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The endogenous microbiota, constituting the microbes that live inside and on humans, is 
estimated to outnumber human cells by a factor of ten. This commensal microbial population 
has an important role in many physiological functions, with the densest microbiota 
population found in the colon. The colonic microbiota is a highly complex and diverse 
bacterial ecosystem, and a delicate balance exists between the gut microbiota and its host. An 
imbalance in the microbial ecosystem may lead to severe symptoms in and also beyond the 
gastrointestinal tract. 
Due to the important role of the gut microbiota in human health, means of its modification 
have been introduced in the dietary concepts of pro-, pre- and synbiotics. Prebiotics, which 
are usually carbohydrates, strive to selectively influence beneficial microbes resident in the 
colon with the aim of modifying the composition and functionality of the commensal 
microbial population towards a purportedly healthier one. The study of prebiotic effects on 
colonic micro-organisms is typically done by using human faecal material, though this 
provides relatively little information on bacterial populations and metabolic events in 
different parts of the colon. For this reason, several in vitro models have been developed to 
investigate the gut microbiota. 
The aim of this doctoral thesis was to screen through some of the promising prebiotic 
candidates, characterize their effects on the microbiota through the use of two in vitro 
methods (pure microbial cultures and a colon simulator model) and to evaluate their potential 
as emerging prebiotics or synbiotics when combined with the probiotic Bifidobacterium 
lactis. 
As a result of the screening work and subsequent colon simulation studies, several 
compounds with promising features were identified. Xylo-oligosaccharides (XOS), which 
have previously already shown promise as prebiotic compounds, were well fermented by 
several probiotic Bifidobacterium lactis strains in pure culture studies and in the following 
simulation studies utilizing the complex microbiota by endogenous B. lactis. Another 
promising compound was panose, a trisaccharide belonging to isomalto-oligosaccharides 
(IMO) that also was also able to modify the microbiota in vitro by increasing the number of 
beneficial microbes investigated. Panose has not been widely studied previously and 
therefore, this thesis work provided the first data on panose fermentation in mixed colonic 
microbiota. Galacto-oligosaccharide (GOS) is an established prebiotic, and it was studied 
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here in conjunction with another potential polygosaccharide polydextrose (PDX) and 
probiotic B. lactis Bi-07. In this final study, the synbiotics including GOS were more 
effective than the constituting pro- or prebiotics alone in modulating the microbiota 
composition, thus indicating a synergy resulting from the combination.  
The results obtained in this in vitro work can be, and have already been, utilized in product 
development aimed at the nutritional modification of the human colonic microbiota. Some of 
the compounds have entered the human clinical intervention phase to investigate in more 




BA = biogenic amines 
BCFA = branched chain fatty acid 
CD = Crohn‟s disease 
CFU = colony forming unit 
DGGE = denaturing gradient gel electrophoresis 
DNA = deoxyribonucleic acid 
EFSA = European Food Safety Authority 
FISH = fluorescence in situ hybridization 
FOS = fructo-oligosaccharides 
GOS = galacto-oligosaccharides 
GIT = gastrointestinal tract 
GLP-1 = glucagon-like peptide -1 
HPLC = high-performance liquid chromatography 
IBS = irritable bowel syndrome 
IBD = inflammatory bodel disease 
IMO = isomalto-oligosaccharides 
MRS = de Man, Rogosa, and Sharpe medium 
OD = optical density 
PDX = polydextrose 
qPCR = quantitative polymerase chain reaction 
SCFA = short chain fatty acid 
SEM = standard error of mean 
SHIME = simulator for human intestinal microbiological ecosystem 
SOS = soy-oligosaccharides 
TIM = TNO intestinal model 
TSB = tryptic soy broth 
V1 = vessel 1 
V2 = vessel 2 
V3 = vessel 3 
V4 = vessel 4 
XOS = xylo-oligosaccharides 
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1. REVIEW OF THE LITERATURE 
1.1. Introduction 
The microbes that live inside and on humans constitute the resident microbiota, which is 
estimated to outnumber the human cells by a factor of ten (Turnbaugh et al., 2007). This huge 
commensal microbial population has an important role in many physiological functions and 
in the colon, where the most dense microbiota can be found, it takes part for example in the 
digestion of food, which is a complex co-operation of human and microbe driven functions 
(Macfarlane and Englyst, 1986). The colonic microbiota is a highly complex and diverse 
bacterial ecosystem, and a delicate balance exists between the gut microbiota and its host. An 
upset in the microbial ecosystem may lead to severe symptoms in and also beyond the 
gastrointestinal tract. The role of the microbiota in the health and disease of the host started to 
be unravelled by Metchnikoff and Tissier over 100 years ago. Metchnikoff ascribed the 
longevity of Bulgarians to the consumption of fermented sour milks, while Tissier discovered 
bifidobacteria in the faeces of breast-fed infants (Fuller and Gibson, 1997; Gibson and Fuller, 
2000). More recently, the composition and activity of the endogenous microbiota of the gut 
have been intensively studied, which has led to the development of a vast array of new 
molecular techniques used to investigate the microbial ecology in health and the composition 
shifts in disease (Furrie, 2006; Tannock, 2008).  
 
Due to the important role of the gut microbiota in human health, means of dietary 
modification have been introduced in the concepts of probiotics (Fuller, 1989) and prebiotics 
(Gibson and Roberfroid, 1995). These aim to modify the composition and/or activity of the 
microbiota towards a purportedly healthier one. Probiotics, being live microbial supplements, 
aim to do this through incorporating beneficial exogenous microbes into the endogenous 
microbiota, whereas prebiotics strive to selectively influence the beneficial microbes already 
resident in the colon. Synbiotics, combinations of pro-and prebiotics, try to benefit from both 
of its constituent components‟ features, and increase the probiotics function by providing 
specific nutrition to it through the prebiotic component (de Vrese and Schrezenmeir, 2008).   
 
The study of prebiotic compounds has relied quite heavily on the investigation of human 
faecal samples as representative samples from other parts of the gastrointestinal tract (GIT) 
are rather difficult to obtain. In vitro models of the human GIT have proven to be useful tools 
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in studying prebiotic fermentation in more detail as they allow the monitoring of prebiotic 
fermentation in different artificial compartments of the GIT and provide information on the 
metabolites produced and the microbial groups affected by the different substrates. 
Furthermore, they allow the analysis of bacterial enzyme activities and toxin formations 
potentially associated with the beneficial and harmful effects and are good models for 
localizing the site of the prebiotic effect. The in vitro models have been successfully used in 
selecting the potential candidates showing prebiotic effects for further in vivo and human 
studies, which remain the obligatory steps in verifying the prebiotic effect of an ingredient 
(Roberfroid et al., 2010).  
1.2. The microbiota of the colon 
1.2.1. Composition of the microbiota  
The human gastrointestinal tract is colonized by microbes from the mouth to the end of the 
large intestine. The numbers of bacteria vary in different regions of the GIT in accordance 
with the prevailing conditions; the colon has the most favorable conditions for microbial 
growth, thus, it is the most heavily colonized part if the GIT (Vernazza et al., 2006b). In an 
adult, the colon is estimated to contain about 800 different bacterial species (Bäckhed et al., 




 bacteria in total (Gill et al., 2006). The majority of 
these microbes are strict anaerobes, and facultative anaerobes and aerobes are present in 
lower numbers (Salminen et al., 1998). In addition to bacteria, the human colon also contains 
eukarya, archaea and viruses (Bäckhed et al., 2005). During the past decade, the progress 
made in molecular techniques has enabled new ways to investigate human microbiota, the 
research of which had previously relied completely on the culturability of the microbes. At 
the turn of the century, it was estimated that between 60%and 80% of adult colonic microbes 
represented putative novel species, most of which have so far not been identified through 
cultivation (Suau et al., 1999). Based on molecular analysis, the majority of colonic microbes 
belong to three major bacterial divisions: Bacteroidetes, Firmicutes (containing e.g. 
Clostridium leptum, Cl. Coccoides-Eubacterium rectale and Lactobacillus as subgroups) and 
Actinobacteria (e.g. Bifidobacterium and Atopobium). The two dominant groups, Cl. 
coccoides-Eubacterium rectale (28%) and Cl. leptum (25%) make up more than half of the 
total microbiota and the most abundant microbial groups after them are Bacteroides (9%), 
Bifidobacterium (4%) and Atopobium (3%). The Lactobacillus-Enterococcus group 
represents approximately 2% of the total microbial population (Lay et al., 2005). Molecular 
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analyses have also revealed that the composition of the human intestinal microbial population 
is host-specific (Eckburg et al., 2005; Ley et al., 2006) and relatively stable over time 
(Rajilic-Stojanovic et al., 2009; Seksik et al., 2003). Furthermore, recent metagenome 
sequencing data suggest the existence of a common core human microbiome (Qin et al., 
2010), although this core may exist more at the level of shared functional genes rather than 
shared common taxa (Turnbaugh et al, 2009); the high degree of diversity between 
individuals in the composition of the microbial community suggests a functional redundancy 
in the gut ecosystem. Many different bacterial species can probably carry out the same 
metabolic functions and thus there is an opportunity for different bacterial species to fill a 
specific ecological niche in the healthy, ”normal” ecosystem (Tannock, 2008). Perhaps, 
therefore, it has been rather difficult to define the composition of the ”normal” microbiota in 
humans, as large deviations within the ”normal range” can occur.   
1.2.2. The role of microbiota composition in health and disease 
The colonizing microbiota is essential to host development and health. Studies on germ-free 
animals have highlighted the importance of the microbial stimulus to the host, as the absence 
of microbiota causes adverse changes in intestinal morphology, absorptive function, motility, 
enteroendocrine and exocrine functions and development of immunity (Smith et al., 2007). 
The major functions attributed to the endogenous microbiota are the fermentation of 
undigested food components and the production of energy for the host (Bäckhed et al., 2005), 
the colonization barrier against invading pathogens (Gibson et al., 2005) and the stimulation 
of the immune system (Macpherson and Harris, 2004); the endogenous microbiota has been 
shown to influence the development of immune system in infants, and its correct 
establishment from birth onwards is considered to have long-lasting implications for the 
health and disease of the host (Kalliomäki et al., 2001; Ouwehand et al., 2001; Gueimonde et 
al., 2007; Sjögren et al., 2009). 
The composition of the microbiota in health and disease has been investigated intensively 
using molecular biological methods and the altered balance between the members of the 
microbiota has been identified in various gastrointestinal tract disorders, such as Clostridium 
difficile –associated diarrhea (Chang et al., 2008), irritable bowel syndrome (IBS; Salonen et 
al., 2010; Lee and Tack 2010; Cremon et al., 2010) and inflammatory bowel diseases (IBD; 
Manichanh et al. 2006; Qin et al., 2010; Frank et al., 2007). Furthermore, even non-gut 
related disorders such as obesity (Ley et al., 2010), atopic eczema (Björksten et al., 2001; 
Kalliomäki et al., 2001), rheumatoid arthritis (Eerola et al., 1994; Toivanen 2003; Vaahtovuo 
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et al., 2008) and autism (Parracho et al., 2005) have been correlated with the altered 
composition and/or functionality of this microbial population. 
According to recent metagenomic studies, the microbiota balance and functionality are also 
altered with advancing age, which might affect the homeostasis between the gut microbiota 
and the host‟s immune system and contribute to the progression of diseases and frailty in the 
elderly (Rajilic-Stojanovic et al., 2009; Biagi et al., 2010).  
1.2.3. Metabolic acitivity of the microbiota 
Through the fermentation of undigested food components, the colonic microbiota contributes 
greatly to the net energy gain of the host from its diet (Wostmann et al., 1983), and the 
amount of energy that can be harvested from the food is affected by the microbiota 
composition (Bäckhed et al., 2004; Turnbaugh et al., 2006). In addition to energy production, 
the gut bacteria are also involved in vitamin synthesis, especially of vitamins B and K 
(Salminen et al., 1998; Smith et al., 2007), and have the capacity to produce and modify 
hundreds of metabolites that affect intestinal health and immunity, as recently highlighted in 
metabolomic studies (Jacobs et al., 2009).   
It has been estimated that, on a daily basis, 10-60g of carbohydrates and 6-18g of protein or 
amino acids reach the human colon and that these substrates are converted by bacteria into a 
range of metabolites (Cummings and Macfarlane, 1991), which are either used by the 
microbes, absorbed into the epithelia and systemic blood circulation, or excreted in feaces. 
The colonic microbiota contains bacteria that derive their energy solely from saccharolytic 
fermentation (e.g. Bifidobacterium and Ruminococcus) or proteolytic fermentation (e.g. 
Peptococcus) although many of the bacteria (e.g. Clostridium, Bacteroides, 
Propionibacterium, Streptococcus Lactobacillus and Eubacterium) are able toderive their 
energy through either type of fermentation, depending on the availability of the substrates 
(Salminen et al., 1998; Hughes et al., 2000). Furthermore, microbes are able to utilise, and 
may even depend on, metabolites produced by other microbes; for instance, lactate and 
acetate, produced by lactic acid bacteria, can be further converted to butyrate by other colonic 
microbes that possibly are not able to utilize the original substrate (Belenguer et al., 2006; 
Duncan et al., 2004). This cross-feeding reflects the ability of microbial species to adapt to 
the limited availability of nutrients, especially in the distal gut (Gibson and Wang, 1994c), as 
significant regional differences in the colon exist in terms of substrate availability. The 
caecum receives digesta from the small intestine and this proximal part of the colon is 
characterized by both high substrate availability and high bacterial activity in terms 
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saccharolytic fermentation; and a faster transit time and low pH, due to the high 
concentrations of fermentation metabolites. The distal part of the colon, on the other hand, 
becomes progressively more depleted in nutrients, the fermentation of proteins and amino 
acids is quantitatively more dominant in the left colon and the pH is close to neutral 
(Cummings and Macfarlane, 1991; Macfarlane et al., 1992).  
 
Fiber and oligosaccharides (e.g. lactose, raffinose, xylitol and prebiotics) that either resist 
digestion or are poorly digested in the small intestine are metabolized by the saccharolytic 
bacteria to produce short chain fatty acids (SCFA), lactate, hydrogen (H2) and carbon dioxide 
(CO2) (Wong et al., 2006). SCFAs, namely acetate, propionate and butyrate, derive mainly 
from carbohydrate fermentation, although protein fermentation also contributes to their 
production, and the substrate availability, microbiota composition and intestinal transit time 
all affect the amount and types of SCFAs (and other metabolites) produced (Macfarlane and 
Macfarlane, 2003). SCFAs are very efficiently absorbed from the colon as only 5-10% of the 
produced SCFA is excreted in faeces (Cummings and Macfarlane, 1991), and their absorption 
is associated with enhanced water and sodium absorption and bicarbonate excretion from the 
colon. Amongst the SCFAs, butyrate is the most widely studied and has been implicated in 
the maintenance of colonic health. It is the preferred energy source of the colonic epithelial 
cells as between 70% and 90% of produced butyrate is metabolized by the colonocytes 
(Wong et al., 2006), and some evidence exists that butyrate exerts various positive effects, 
such as the inhibition of colon carcinogenesis, decreased inflammation and oxidative stress, 
and improvement of the colonic barrier function (Hamer et al., 2008; Scheppach and Weiler, 
2004). Acetate is the principal SCFA in the colon and is mainly absorbed and utilised 
systemically in peripheral tissues (liver, brain, cardiac and skeletal muscle). It is used as a 
substrate for cholesterol and fatty acid synthesis in the liver, and also as a precursor for 
gluconeogenesis. Propionate is also absorbed from the colon and used by the liver cells in 
gluconeogenesis (Wong et al., 2006). In animals, propionate inhibits the uptake of acetate 
into the cholesterol synthesis pathway, and reduces the levels of serum cholesterol. In 
humans, the same effect has not been as pronounced (Hara et al., 1999; Salminen et al., 
1998).  
 
Dietary protein enters the colon in small quantities, as do host-derived substances like mucin 
glycoproteins, digestive enzymes and exfoliated epithelial cells. Both dietary and host 
derived proteins contribute to proteolytic fermentation, which produces e.g. ammonia, 
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phenolic and indolic compounds, N-nitroso compounds, branched chain fatty acids, biogenic 
amines, hydrogen sulphide, CO2 and H2 (Cummings and Macfarlane, 1991). Although 
proteins are important sources of energy for microbes when carbohydrate sources are 
exhausted, some of the proteolytic metabolites (e.g. indoles, hydrogen sulphide and biogenic 
amines) are potentially harmful substances for the host and can exert toxic effects (Hughes et 
al., 2000; Wong et al., 2006). In vitro, in vivo and human studies have demonstrated that high 
colonic protein fermentation contributes to increased toxicity of the intestinal contents and an 
increased risk of colorectal cancer (Santarelli et al., 2008; Hughes et al., 2000; Macfarlane et 
al., 1992), and implications between proteolytic fermentation and inflammatory bowel 
diseases also exist (van Nuenen et al., 2004). Therefore, lowering the concentrations of 
proteolytic metabolites, especially in the distal colon where their concentration is highest, is 
considered to benefit the health of the host (Macfarlane et al., 1992). Fermentable 
carbohydrates have been shown to decrease ammonia in vitro and urinary phenol and p-cresol 
and faecal BCFA concentrations in humans, thus leading to the assumption that 
carbohydrates are the preferred energy source for the gut microbes at the expense of 
proteolytic metabolism (Blachier et al., 2007; Hughes et al., 2000). 
1.3. Modulating the composition of microbiota 
Due to the significance of the roles the microbiota play in both the health and disease of the 
host, attempts have been made to regulate the composition towards a purportedly healthier 
one. Probiotic and prebiotics, and their combination, synbiotics, have been introduced and 
also used successfully in balancing the microbiota.  
Probiotics were first defined as “live microbial feed supplements, which beneficially affect 
the host by improving its intestinal microbial balance” (Fuller, 1989). The original definition 
has since been modified and a probiotic should therefore, in addition to merely modifying the 
intestinal microbiota, confer health benefits to the host when administered in adequate 
amounts (WHO/FAO, 2002). Probiotic microbes usually belong to the genera Lactobacillus 
or Bifidobacterium, which have a long and safe history of use in fermented foods (Mogensen 
et al., 2002a; Mogensen et al., 2002b) and are thought to provide protection towards 
inflammation in breast-fed babies (bifidobacteria), stimulate the immune system, and be 
partly responsible for the colonic barrier function (Macfarlane et al., 2006; Meile et al., 2008; 
Salminen et al., 1998). In addition, the yeast, Saccharomycces boulardii, and some other 
bacteria such as Enterococcus faecium and Lactococcus lactis, have also been used as 
probiotics. In order for a probiotic microbe to confer health benefits to the host, it should 
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remain intact and viable in the GIT and interact with the host and/or the colonic microbiota 
(de Vrese and Schrezenmeir, 2008).  
However, the efficacy and viability of probiotic microbes can be diminished by the protective 
barriers of the human body, such as a low pH and hydrogen chloride in the stomach, digestive 
enzymes in the small intestine and, in the colon, by the endogenous microbiota with which 
they are forced to compete for nutrients and an ecological niche (Tuohy et al., 2005). Thus, 
an alternative prebiotic approach has been introduced (Gibson and Roberfroid, 1995). 
Prebiotics aim to target specific microbial groups already resident in the colon, thus, 
overcoming the main problem encountered with probiotic viability, and produce health 
promoting effects through the modification of the host microbiota composition and/or 
activity. However, the selective fermentation of a prebiotic only by those microbes with 
suggested beneficial activities has been difficult to establish (Saulnier, 2007); the main 
difficulty being that the large proportion of colonic bacteria that are still unidentified and 
their role as part of the healthy microbiota is as yet unknown. Also the inter-individual 
variation and the potential low numbers of beneficial microbes in the gut, e.g. due to diet, 
medication or age, could compromise the efficacy of a prebiotic (Macfarlane et al., 2006). 
Synbiotics, which are combinations of pro- and prebiotics, could possibly overcome the 
limitations encountered with both of the individual components (Saulnier, 2007). Synbiotics 
were defined together with the introduction of prebiotics, and are mixtures of pro- and 
prebiotics that benefit the host by improving the survival and implantation of the selected, 
beneficial microbial dietary supplements. The prebiotic compounds should therefore be 
specific for the probiotic in question and enhance its efficacy in the colon, and should also 
modify the endogenous microbiota in a beneficial manner (Gibson and Roberfroid, 1995). 
However, although the synbiotic approach is an interesting one, only a few combinations of 
pro- and prebiotics can thus far be evaluated as being true synbiotics (Saulnier, 2007; 
Saulnier et al., 2008). The amount of the prebiotic per serving is either too low to ascertain an 
effect, a bifidogenic prebiotic is combined with probiotic lactobacilli, or the synbiotic does 
not show any additional benefits when compared with its pre- and/or probiotic components 
(de Vrese and Schrezenmeir, 2008).   
1.4. Prebiotics 
Prebiotics were defined by Gibson and Roberfroid in 1995 as ”non-digestible food 
ingredients that beneficially affect the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the colon, and thus improve host health.” As 
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with probiotics, the original definition of prebiotics has been updated a few times to 
emphasize certain aspects of the definition (Gibson et al., 2004; Pineiro et al., 2008; 
Roberfroid, 2007) and, according to the latest definition, a prebiotic is a non-viable food 
component that confers a health benefit on the host associated with modulation of the 
microbiota (Pineiro et al., 2008). This defines prebiotics as food-grade components that 
deliver a measurable benefit to the host through the modulation of the microbiota. 
  
The criteria that a prebiotic compound should fulfill are: 
 The compound should be either completely indigestible or poorly digested and either 
not at all or poorly absorbed in the upper gastrointestinal tract, and should enter the 
colon intact. 
 In the colon, the compound should be fermented by beneficial microbial groups 
amongst the endogenous microbiota and result in increased numbers of beneficial 
microbes and/or their metabolic products. 
 The increased microbial mass and/or metabolites deriving from the prebiotic 
fermentation should lead to measurable health effects on the host. 
 
Research into prebiotics began long before its definition, when bifidogenic factors in human 
milk were identified. Researchers concluded that some components of the milk improved the 
quality of the faeces in breast-fed infants (increased bifidobacteria) and in their health, in 
comparison to formula-fed ones. Thus, human milk oligosaccharides could be considered as 
the first and most natural prebiotic compounds (Coppa et al., 2004). Thereafter, several oligo- 
and polysaccharides have been addressed as being prebiotics over the past decades, but only a 
few are truly considered to be such (Gibson et al., 2004). Fructo-oligosaccharides (FOS) are 
the ”gold standard” of prebiotics and have been studied the most by far. Galacto-
oligosaccharides (GOS) and lactulose also fulfill the current criteria of prebiotics. 
Nevertheless, as commercial interest towards functional food ingredients and gut health has 
grown, an increasing amount of compounds with promising prebiotic features have emerged. 
These include xylo-oligosaccharides (XOS), lactitol, polydextrose, isomalto-oligosaccharides 
(IMO) and soy-oligosaccharides (SOS) to name a few (Gibson et al., 2004; Jie et al., 2000; 
Tuohy et al., 2005). Vey recently, cocoa-derives flavonols have also been reported to 
selectively modify the microbiota in humans (Tzounis et al., 2011), thus expanding the field 
of prebiotic compounds from oligo- and polysaccharides to plant polyphenols. 
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Prebiotic compounds mediate their actions mainly through the microbiota (exogenous 
probiotics or resident gut microbes), inducing microbial growth and the resultant metabolic 
activity leads to desired health effects (Ouwehand et al., 2005). Through the endogenous 
microbes, prebiotics may influence the immune system (Moro et al., 2006; Arslanoglu et al., 
2007, 2008), increase biomass in the colon (Gibson et al., 1995; Castiglia-Delavaud et al., 
1998) and inhibit pathogenic growth by decreasing luminal pH and producing anti-microbial 
agents (Fooks and Gibson, 2002, 2003; Hopkins and Macfarlane, 2003). It has been also 
noted that prebiotics may increase the elimination of toxins (xenobiotics) from the colon by 
affecting the microbiota composition or activity (Reid et al., 2003; Zampa et al., 2004; 
Kimura et al., 2004). Microbes produce SCFAs from prebiotics, and these acids can possibly 
influence several functions in the gut: relieve constipation, inhibit pathogenic growth, 
improve absorption of minerals and affects cholesterol synthesis in the liver (Topping and 
Clifton, 2001; Wong et al., 2006). Butyrate is especially important for the colonocytes as it 
provides nutrition for them and promotes correct cell differentiation (Hamer et al., 2008). 
Prebiotics may also have direct effects on the colonocytes and immune cells in the gut 































Figure 1. Possible mechanisms of prebiotic action in the colon. Solid lines indicate relatively 
established modes of action, whereas dotted lines indicate a less well-established mode of 
action (modified from Ouwehand et al., 2005). 
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The effects arising from the prebiotic actions in the colon have been intensively studied over 
the past two decades. The research has mainly focused on identifying the microbial groups 
among the gut microbiota that are affected by the prebiotic fermentation, and attempting to 
correlate these modifications with a health benefit. Bifidobacteria and Lactobacillus are the 
microbes that have traditionally been the most intensively studied because they benefit the 
host (Fuller and Gibson, 1997) and are easily quantified with classical cultivation techniques. 
A large number of human intervention studies have also linked the consumption of prebiotic 
ingredients to increased levels of bifidobacteria and/or lactobacilli while some studies have 
also reported reductions in the concentrations of commensal and potentially pathogenic 
bacteria, such as Salmonella, Bacteroides and clostridia, with prebiotic consumption 
(Roberfroid et al., 2010; Macfarlane et al., 2006). However, as knowledge on the previously 
unknown members of the microbiota is accumulating, the traditional division of microbiota 
into solely good (bifidobacteria and lactobacilli) and bad (clostridia and Bacteroides) 
components is perhaps too simplified, and it seems clear that other members of the gut 
microbiota are also affected by the prebiotics. For instance, the group Bacteroides contains 
species with not only potentially beneficial, but also detrimental properties (Wexler, 2007), 
and the beneficial prebiotic effects could be mediated through the increased numbers or 
activities of butyrate-producing microbes, e.g. the Eubacterium rectale/Roseburia species and 
Feacalibacterium prausnitzii, belonging to clostridial clusters IV and XIVa (Louis and Flint, 
2009). The decreased levels of these microbes have been recently linked to IBD (Sokol et al., 
2008; Takaishi et al., 2008), and their faecal levels strongly correlate with faecal butyrate 
concentrations. Furthermore, the levels of these microbes are modifiable with dietary 
carbohydrates and fibre (Benus et al., 2010; Duncan et al., 2007) and thus they may also 
respond to prebiotic supplementation. In addition to the various members of the gut 
microbiota, the role of their vast metabolic activity in improved function and/or the reduced 
risk of a disease associated with the prebiotic effect has been recently highlighted (Jacobs et 
al. 2009). 
 
Although the definite causality of the prebiotic effect still remains to be answered, there is 
evidence that links the modification of the gut microbiota and its functionality to some 
gastrointestinal and systemic health effects. Table 1 summarizes the proposed targets for 
prebiotic effects, which are anticipated to be associated with the stimulation of growth and/or 
the activities of a limited number of gut microbes, and tentatively to a health effect and/or 
reduced risk of a disease (Roberfroid et al., 2010).  
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Table 1. Proposed targets for prebiotic effects (modified from Roberfroid et al., 2010). 
 
Modification of colonic microbiota composition
Improvement of gastrointestinal tract functions (faecal bulking, regularity, consistency)
Increase in mineral absorbtion and improved bone structure
Modulation of gastrointestinal peptide production related to satiety and energy intake
Initiation of proper immune function development and regulation after birth (atopic diseases, infections)
Improvement of intestinal barrier functions
Reducing the risk of gastrointestinal infections and inflammation
Reducing the risk of colon cancer
Modulation of cholesterol synthesis in liver
Reducing the risk of obesity, metabolic syndrome and adult-type diabetes  
 
1.4.1. Established prebiotics; effects on the microbiota composition, functionality and 
health of the host 
In Europe, inulin type fructans, galacto-oligosaccharides and lactulose have been shown to 
fulfil all the criteria of a prebiotic compound, based on results from in vitro studies and 
human interventions that provide sufficient evidence of their non-digestibility, ability to 
change the gut microbiota composition and confer health benefits to the consumer (Kolida 
and Gibson, 2007).  
 
1.4.1.1. Fructo-oligosaccharides and inulin 
Inulin and FOS are polymers of fructose, linked by β (2-1) bonds with a terminal glucose at 
the end of the molecule. FOS are oligosaccharides with a degree of polymerization between 2 
and 10 and polysaccharides larger than that are referred to as inulin (Crittenden and Playne, 
1996). Inulin and other fructans are present in relatively high concentrations in a number of 
natural foods, such as chicory, onion, Jerusalem artichokes and asparagus. Commercial FOS 
are produced by enzymatic hydrolysis from inulin, or synthesized from sucrose (Brown and 
Tuohy, 2006).  
In one of the first articles published on FOS fermentation by colonic microbes, Gibson and 
Wang (1994a) demonstrated in vitro, using selective plating methods, the bifidogenic 
properties of FOS with concomitant suppression of Bacteroides, clostridia and coliforms in 
mixed faecal culture in a colon model. Later in vitro studies using culture-independent 
molecular techniques have also demonstrated the modulatory properties of FOS and inulin 
(Rycroft et al., 2001a; Sghir et al., 1998; van de Wiele et al., 2007) and in several human 
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interventions, increased levels of Bifidobacterium and Lactobacillus and decreased levels of 
enterococci, fusobacteria and/or Bacteroides have been confirmed, utilising molecular 
techniques to assess the microbiota composition (Kolida et al., 2007;Kruse et al., 1999; 
Bouhnik et al., 1999). Bifidogenicity is also evident when FOS and inulin are delivered in 
different food matrixes, such as bakery products (Tuohy et al., 2001; Kleessen et al., 2007) 
and fruit and vegetable drinks (Ramnani et al., 2010). The sufficient dose for the bifidogenic 
effect for inulin is between 5-8g/day (Kolida et al., 2007; Kolida and Gibson, 2007) and for 
FOS between 4-10g/day (Bouhnik et al., 1999; Buddington et al., 1996), although the 
magnitude of the increased proportion of bifidobacteria depends on the initial population 
levels (Tuohy et al., 2001; Kolida et al., 2007). The same holds true for other prebiotics, such 
as GOS and PDX (Tiihonen et al., 2008). The fermentation activity of the microbiota is also 
modified as a result of FOS and inulin consumption, which leads to increased SCFA 
production, especially of acetate and butyrate (Rycroft et al., 2001a; Kleessen et al., 2001). 
 
 
Figure 2. Molecular structure of FOS (dp=3) 
 
 
The health effects associated with FOS and inulin have been 
investigated in relation to several conditions. For instance, in patients 
with IBD (Crohn‟s disease, CD), some evidence exists on the 
effectiveness of FOS and inulin to improve colonic inflammation and 
related symptoms (Hussey et al., 2003) with a concomitant increase in intestinal 
Bifidobacterium numbers (Lindsay et al., 2006). Recent evidence also suggests that inulin-
type fructans might be able to modulate the release of hormones associated with appetite 
control (plasma GLP-1 and peptide YY), thereby affecting the gut-brain axis of appetite 
regulation (Bosscher and Van Loo, 2008). Increased postbrandial satiety, lower hunger rates 
and a subsequently decreased total energy intake during meals following prebiotic 
consumption have been demonstrated (Cani et al., 2006), and furthermore, satiety increasing 
effects were evident in both a short-term two-week intervention (Cani et al., 2009) and in a 
long-term 12-month study on adolescent girls and boys (n=100) (Abrams et al., 2007). Some 
indications of the role of FOS and inulin on improved mineral absorption (calcium and 
magnesium) from the colon and a consequently improved bone turnover rate exist (van den 
Heuvel et al., 1999; Younes et al., 2001; Scholz-Ahrens et al., 2002; Holloway et al., 2007) 
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although the evidence is mainly experimental and human studies have shown contradictory 
results (Griffin et al., 2002; Tahiri et al., 2003; van den Heuvel et al., 2009). Nevertheless, 
consumption of high doses of FOS (20g/day) may also cause inverse gastrointestinal 
symptoms, such as flatulence and bloating, which could derive from the (too) rapid 
fermentation of FOS, leading to an accumulation of lactate that would otherwise normally be 
metabolized further into SCFAs, and inducing mucin secretion, reflecting irritation and 
impairment of the intestinal barrier (Ten Bruggencate et al., 2005, 2006). In rats, FOS and 
inulin have even been suggested in certain conditions to enhance the colonization and 
transloction of Salmonella enteric serovar Enteriditis (Ten Bruggencate et al., 2003, 2004). 
 
1.4.1.2. Galacto-oligosaccharides 
Galacto-oligosaccharides (GOS), sometimes referred to as trans-galacto-oligosaccharides 
(TOS), are naturally present in human milk but can also be manufactured from lactose by 
transglycosylation reactions. GOS consist of galactosyl derivatives of lactose with beta β (1-
4) and β (1-6) –linkages and the degree of polymerization (dp) is usually between 2 to 5 
(Crittenden and Playne, 1996). Alongside FOS, galacto-oligosaccharides (GOS) have an 
established prebiotic status and their health effects been extensively studied (Gibson et al., 
2004; Roberfroid, 2007).  
In pure cultures, GOS was fermented well by all bifidobacteria and moderately by a few 
Bacteroides and Lactobacillus among the 55 strains tested in vitro (Tanaka et al., 1983); and 
in faecal slurries, GOS most significantly increased bifidobacterial growth and decreased Cl. 
histolyticum group members in all the prebiotics tested (GOS, FOS, inulin, XOS, IMO, 
lactulose and SOS), as measured with fluorescence in situ hybridization (FISH; Rycroft et al., 
2001a). Similarly in pigs, GOS (at 4% of the diet) consumption increased the numbers of 
bifidobacteria and lactobacilli in the proximal and distal colon, whereas other determined 
microbes (Bacteroides spp. and Cl. histolyticum group members) were unaffected; and GOS 
were more efficient in modulating the microbiota than inulin in the same experiment 
(Tzortzis et al., 2005). In human feeding trials, the bifidogenic properties of GOS have been 
demonstrated together with other modifications of the microbiota and microbial enzyme 
activities (Tuohy et al., 2005). With a daily dose ranging from 2.4g to 7g/day, GOS has been 
shown to significantly increase Bifidobacterium numbers (Depeint et al., 2008; Vulevic et al., 
2008; Silk et al., 2009; Gopal et al., 2003) and to also affect other bacterial groups in the 
microbiota, as increased levels of Lactobacillus-Enterococcus spp. and Cl. coccoides/Eub. 
rectale group and decreased numbers of Bacteroides-Prevotella and Cl. histolyticum groups, 
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E. coli and Desulfovibrio spp. have been demonstrated with culture-independent techniques 
(Vulevic et al., 2008).  
The fermentation of GOS in rats resulted in increased levels of SCFAs, a decreased colonic 
pH and a decrease in the production of the potentially toxic proteolytic metabolites p-cresol 
and indole (Tanaka et al., 1983). In humans, the faecal concentrations of acetate are increased 
after GOS consumption (Bouhnik et al., 1997) and the markers of proteolytic fermentation 
(BCFA, p-cresol and indole) are decreased (Ito et al., 1993). 
 
Figure 3. Molecular structure of GOS 
(dp=3) 
 
The establishment of high levels of 
bifidobacteria in the infant gut has been 
attributed to the presence of galactose-
containing oligosaccharides in human 
milk; thus, the inclusion of GOS to infant 
formulas has attracted considerable commercial interest (Crittenden and Playne, 1996) and 
these prebiotic supplemented formulas (GOS and FOS, 9:1) have been shown to modify the 
microbiota of the formula-fed babies in such a way that it resembles that of breast-fed babies 
(Rinne et al., 2005). Furthermore, the inclusion of prebiotics to infant formulas has been 
shown to reduce the cumulative incidence of intestinal and respiratory infections (Arslanoglu 
et al., 2007; Bruzzese et al., 2009) and the cumulative incidence of atopic dermatitis in high 
risk populations during a six-month intervention (Moro et al., 2006) and the protective effects 
prevailed until at least the end of a two-year follow-up period (Arslanoglu et al., 2008). 
However, these studies have been criticized on several grounds for containing several 
weaknesses (EFSA, 2010) and thus the evidence of GOS (and FOS) on enhancing the 
immunity of infants remains inconclusive. GOS (in amounts between 3.5g and 7.0g per day) 
has been shown to help alleviate the symptoms of IBS by reducing flatulence and bloating 
while improving stool consistency in IBS patients during a 12-week study period, thus having 
significant therapeutic value for the IBS patients (n=44) (Silk et al., 2009). Some evidence 
also exists of the preventive effects of GOS on the incidence and duration of traveller‟s 
diarrhea (Drakoularakou et al., 2010) and on the constipation of elderly people (Teuri and 
Korpela, 1998). A positive correlation between the GOS-induced bifidogenicity and the 










































production of anti-inflammatory and inflammatory cytokines) has also been demonstrated in 
healthy elderly volunteers (Vulevic et al., 2008). Whether these changes in the immune 
system relate to actual improvements in immunity, i.e. reducing the risk and/or duration of an 
illness remains to be elucidated.   
 
1.4.1.3. Lactulose 
Lactulose is a synthetic disaccharide (D-galactopyranosyl-D-fructose) derived from the 
isomerization of lactose (Crittenden and Playne, 1996) and is traditionally used as a laxative 
and in the treatment of hepatic encephalopathy (Schumann, 2002). In vitro, lactulose has been 
shown to be fermented by the Lactobacillus, Enterococcus and Streptococcus strains of 
faecal or colonic biopsy origin (Kontula et al., 1999) and to be fermented rapidly in mixed 
faecal cultures, resulting in the high production of SCFAs (Khan and Edwards, 2002). In 
pigs, lactulose feeding has been shown to decrease faecal proportions of culturable aerobic 
bacteria and Cl. perfringens (Krueger et al., 2002). In humans, lactulose ingestion (3-10 
g/day) has been shown to increase faecal bifidobacteria, employing classical culture-based 
methods (Terada et al., 1992; Ballongue et al., 1997; Bouhnik et al., 2004) and culture-
independent methods (FISH) (Tuohy et al., 2002); decreased clostridia were also 
demonstrated in the latter study. Increaed levels of faecal SCFAs with a concomitant decrease 
in potentially pro-carcinogenic faecal enzymes have been demonstrated (Terada et al., 1992). 
In addition to the constipation relieving properties of lactulose, some preliminary evidence 
exists on its beneficial effects on calcium absorption (van den Heuvel et al., 1999a), but this 
proposed health effect requires substantial further investigation. 
 
Figure 4: Molecular structure of lactulose 
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1.4.2. Emerging prebiotics; effects on the microbiota composition, functionality and 
health of the host 
The market for prebiotics in foods is growing rapidly worldwide and in 2007 there were 
already over 400 prebiotic food products marketed (Pineiro et al., 2008). Most of the 
marketed prebiotic-containing products are inulin-based FOS or GOS components, though a 
variety of other potentially prebiotic compounds have been identified, such as isomalto-
oligosaccharides, gentio-oligosaccharides, xylo-oligosaccharides, lactitol and polydextrose. 
However, the ultimate tests for the prebiotic activity, human volunteer trials, are either scarce 
or lacking for the majority of these candidates (Roberfroid et al., 2010) and thus more 
evidence on their efficacy is needed for prebiotic status. Here, the prebiotic candidates used 
in this thesis project are presented in more detail. 
 
1.4.2.1. Xylo-oligosaccharides 
XOS are made up of xylose units and can be produced by enzymatic hydrolysis from xylan, 
the major component of plant hemicelluloses and therefore readily available in nature. XOS 
are relatively stable in acidic conditions, which may endow protection from decomposition 
when passing through the stomach (Imaizumi et al., 1991). The degradation of xylobiose 
(XOS dp=2) in the intestine has been studied in vitro with an artificial model of digestive 
enzymes (-amylase, pancreatin, gastric juice and intestinal brush border enzymes) and no 
hydrolysation of xylobiose was observed (Koga and Fujikawa, 1993). This suggests that XOS 
may be non-digestible or low digestible carbohydrates and would reach the colon intact.  
XOS have been reported to be preferentially fermented by bifidobacteria in vitro. Pure culture 
studies have indicated that XOS are metabolized by many bifidobacteria (B. bifidum, B. 
longum, B. catenulatum, B. lactis and B. adolescentis), whereas other enteric bacterial strains 
(lactobacilli, Bacteroides, clostridia) have not significantly metabolized XOS (Jaskari et al., 
1998; Kontula et al., 1998b; Yong et al., 2001; Crittenden et al., 2002; Palframan et al., 
2003b). Faecal batch fermentations and semi-continuous culture fermentations have also 
shown that XOS stimulated the growth of bifidobacteria (Rycroft et al., 2001b; Zampa et al., 
2004). Trials with rats and mice have demonstrated that XOS stimulated the growth of caecal 
and faecal bifidobacteria at a higher level than FOS (Campbell et al., 1997; Hsu et al., 2004; 
Jaskari et al., 1998; Santos et al., 2006). The growth of other intestinal microbes (clostridia, 
Eubacterium, enterococci, and E. coli) on XOS has been very limited with only some isolates 
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of Bacteroides and clostridia able to degrade XOS to some extent (Crittenden et al., 2002; 
Jaskari et al., 1998).  
In human feeding trials, even low doses of between 2g and 5g of XOS per day have resulted 
in significant increases in culturable faecal bifidobacteria; culturable members of e.g. 
Enterobacteriaceae, Lactobacillus, Bacteroidaceae, Eubacterium, clostridia and Bacillus 
were not affected. Faecal SCFA concentrations were increased, and concomitantly pH and 
proteolytic metabolites and enzyme activites decreased, during the feeding trials (Nakakuki, 
2003; Okazaki et al., 1990). The limitations of these studies are the small number of subjects 
(five, nine and ten men), an uncontrolled study-design and the use of the plating method in 
enumeration of microbes in faeces. Some preliminary evidence exists on the ameliorating 
effects of XOS on constipation in women (Iino et al., 1997; Tateyama et al., 2005) although 












Lactitol is a lactose-derived sugar alcohol constituting of galactose and sorbitol, which is only 
minimally hydrolyzed by the human upper gastrointestinal tract and reaches the colon 
virtually intact (Natah et al., 1997; Nilsson and Jagerstad, 1987). In vitro studies have 
demonstrated that lactic acid bacteria are able to ferment lactitol in pure cultures (Klewicki 
and Klewicka, 2004; Kontula et al., 1999; Saarela et al., 2003) and in simulated colon 
fermentation studies with human faecal inoculum, lactitol was rapidly fermented in the 
proximal colon and increased Bifidobacterium numbers, decreased Clostridium cluster IV 
numbers, but did not affect Lactobacillus or Bacteroidetes numbers (Mäkivuokko et al., 
2010). Lactitol fermentation has been reported to increase the concentrations of SCFAs 
(especially butyric and acetic acids) in human faecal samples (Mäkivuokko et al., 2010; 
Probert et al., 2004), and also in rats (Peuranen et al., 2004); and to lower pH, reduce the 
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concentrations of faecal aromatic compounds (e.g. phenol, cresol, indole and skatole) and 
pro-carcinogenic enzyme activities (e.g. azoreductase, glucuronidase and urease) in humans 
(Ballongue et al., 1997).  
In healthy humans, lactitol consumption (2 x 10g per day) has been shown to increase 
culturable fecal bifidobacteria and lactobacilli while concomitantly decreasing the levels of 
culturable clostridia, Bacteroides and coliforms (Ballongue et al., 1997). The effective dose 
of lactitol was found to be 10g per day, which was sufficient to increase culturable 
Bifidobacterium numbers, decrease faecal pH and increase production of propionic and 
butyric acids (Finney et al., 2007). The Bifidobacterium increasing effects of lactitol have 
also been demonstrated in the healthy elderly, using culture-independent methods (Ouwehand 









Polydextrose (PDX) is a glucose polymer with a highly branched structure (average dp=12). 
It has been recognized as a soluble fiber, and human clinical, animal and in vitro studies have 
all demonstrated physiological effects associated with this feature (Craig et al., 2000). PDX 
reaches the large intestine intact, where it is gradually degraded by the colonic microbes 
(Lahtinen et al., 2010) into butyric, acetic and propionic acids while concomitantly 
decreasing the levels of proteolytic metabolites (BCFA, biogenic amines, phenol, p-cresol 
and indole) (Mitsuoka, 1996; Jie et al., 2000; Mäkeläinen et al., 2007). In vitro, PDX has 
been shown to increase bifidobacteria, assessed by molecular methods, in a mixed faecal 
population using a continuous-culture colon simulator (Probert et al., 2004), although in 
another similar apparatus, the bifidogenic effects were not reproduced, even if a gradual, slow 
fermentation of PDX by the microbiota was evident (Mäkeläinen et al., 2007; Mäkivuokko et 
al., 2005). In a placebo-controlled, randomized, double-blind human intervention (n=120), 
significant increases in the numbers of culturable bifidobacteria and lactobacilli together with 
decreased Bacteroides numbers were demonstrated (Jie et al., 2000). Improved bowel 
function has been demonstrated with daily intake of 4–12g PDX with no adverse effects, such 
 
HO 














as abdominal distension, cramps or diarrhea reported (Jie et al., 2000). Shortened oro-faecal 
time has also been demonstrated, implicating the role of PDX in alleviating constipation 
(Hengst et al., 2008). Therefore, some evidence on the prebiotic potential of PDX exists, 
although more research is needed to confirm the status.  
 
 
Figure 7. Molecular structure of polydextrose 
 
1.6.2.4. Isomalto-oligosaccharides 
Isomalto-oligosaccharides (IMO) are a mixture of oligosaccharides, consisting of glucose 
units (dp=2-5) which are bound with linear α (1-6) glycosidic linkages but which also contain 
branched molecules with α (1-4) linkages. IMOs can be produced from starch (Crittenden and 
Playne, 1996). The digestibility of IMO mixtures has been investigated in a study by 
Kohmoto and co-workers (1992), where the expiration rates of excess 
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CO2 and hydrogen 
were measured in six men after IMO ingestion. The results indicated that IMO would be 
partly digested and partly fermented by the endogenous microbiota in the colon. In another 
study, with rat jejunum loops, IMO was shown to be slowly digested and those components 
with higher degree of polymerization (isomaltotriose, -tetraose and –pentose) were less 
digestible than isomaltose (Kaneko et al. 1995). 
IMOs have been shown to be very well fermented by bifidobacteria, Bacteroides, and 
Enterococcus faecalis, but not by E. coli or other tested bacterial populations in pure cultures 
(Kohmoto et al., 1988). In 24h static batch cultures, IMO increased Bifidobacterium numbers 
significantly and caused increased production of acetate, lactate and propionate (Rycroft et 
al., 2001a). In humans, IMO fermentation was shown to increase faecal Bifidobacterium 
B 
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levels significantly in a dose-dependent manner (Kaneko et al., 1994; Kohmoto et al., 1988; 
Kohmoto et al., 1991). Increased Bacteroidaceae levels were also measured in one of the 
human interventions (Kohmoto et al., 1988). The sufficient dose for bifidogenic effect 
seemed to be 5g per day, although higher doses (10-20g per day) resulted in more profound 
and faster increases in bifidobacteria. The evidence that supports the prebiotic status for IMO 
is therefore promising, but remains as yet insufficient (Gibson et al., 2004).  
 
1.4.2.4. Panose 
Panose is a trisaccharide (dp=3) with 1-4 and 1-6 linkages (alpha-D-Glc-(1→6)-alpha-D-Glc-
(1→4)-D-Glc), and it is classified as an isomalto-oligosaccharide (IMO) (Kohmoto et al., 
1988). Studies assessing the (in)digestibility of IMO mixtures containing panose in humans 
indicate that IMOs would be partly digested in the small intestine and partly fermented by the 
endogenous microbiota in the colon (Kohmoto et al., 1992). The fermentation of pure panose 
by colonic microbes has been studied only in pure cultures, where it was utilized by few 
Bifidobacterium and Bacteroides strains, Enterococcus feacalis and Clostridium ramosum. A 
range of other tested enteric bacteria (n=37, e.g. lactobacilli, Eubacterium, E.coli, clostridia, 
Fusobacterium stains) were not able to metabolize panose (Kohmoto et al., 1988). In a few 
human studies, panose has been investigated only as part of an IMO mixture (Isomalto-900® 
containing 7% panose, or IMO3 containing 28% panose), which increased the culturable 
bifidobacteria in the faeces of healthy men and elderly persons without affecting a range of 
other bacterial groups and yeasts (Kaneko et al., 1994; Kohmoto et al., 1988; Kohmoto et al., 
1991). The fermentation of pure panose in human interventions has not yet been investigated.  
  
 
Figure 8. Molecular structures of 

































































Pullulan is an extracellular polysaccharide excreted by the filamentous fungus Aureobasidium 
pullulans, consisting of maltotriose units (such as panose) linked through α (1→6) glycosidic 
bonds. Pullulan is partly digested and absorbed in the small intestine of humans, and partly 
fermented in the large intestine (Wolf et al., 2003). Fermentation of pullulan has been studied 
using human faecal bacteria and the increased production of SCFAs was measured (Spears et 
al., 2007). No studies on humans investigating the effects of pullulan on gut microbiota have 
been performed so far.  
 
 





Sophorose is a disaccharide (dp=2) with 1-2 linkage between the glucose molecules (beta-D-
Glc-(1→2)-D-Glc). No data on the indigestibility of sophorose in the small intestine was 
found. In a study by Sanz et al. (Sanz et al., 2005), sophorose was analyzed among tens of 
other carbohydrates with a small-scale in vitro batch fermentor with faecal inoculums. Of all 
the substrates, fermentation of sophorose resulted in the highest increases in bifidobacterial 
populations, even significantly higher than those resulting from the established prebiotic, 
FOS. When the changes in other measured microbial groups (Bacteroides and Cl. 
histolyticum groups) were also considered with molecular biology methods, sophorose 
showed the highest selectivity towards desirable colonic bacteria (Palframan et al., 2003a). 
 







Gentiobiose is a disaccharide (dp=2) that is composed of glucose units with a β (1→6) 
linkage. No data on the indigestibility of gentiobiose in the small intestine has been reported, 
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and thus far, neither gentiobiose nor gentio-oligosaccharides have been studied in great depth.  
Sanz and co-workers (2005) studied the structure-function effects of a range of carbohydrates 
in small-scale in vitro fermentations with human faecal inoculum and in these studies 
gentiobiose did not enhance the growth of bifidobacteria or lactobacilli (Bacteroides, 
Clostridium histolyticum groups were also investigated, with FISH) but produced a high 
increase in lactic and acetic acids during the fermentation. Gentio-oligosaccharides with 
varying degree of polymerization (dp 1-5) have also been studied in a batch-fermentor, where 
gentio-oligosaccharides produced higher increases in bifidobacteria and lactobacilli 








Xylitol is a five-carbon polyalcohol that is best known for its anticariogenic properties (Burt, 
2006). It is widely used as a sugar substitute in chewing gums, dentistry products and 
confectionery (Burt, 2006; Touger-Decker and van Loveren, 2003); the European Food 
Safety authorities (EFSA) has positively evaluated the health claim (reducing the risk of tooth 
decay) in chewing gum and pastilles with 100% xylitol (EFSA, 2008). Ingestion of xylitol is 
associated with only minor changes in the plasma levels of glucose, insulin and glucose-
independent insulinotrophic peptide (GIP), indicating that only a portion of xylitol is 
absorbed in the upper gastrointestinal tract and that it is mostly metabolized in the colon 
(Natah et al., 1997; Salminen et al., 1989). Estimates of the extent of xylitol fermentation in 
the colon range between 50% and 75% (Livesey, 2003). The microbial fermentation of 
xylitol in the colon is still largely unknown and has previously been studied only with 
selective plating methods (Salminen et al., 1985).  
 




1.5. Characterizing prebiotic fermentation in the colon 
Investigation of the prebiotic effects in humans is usually conducted by assessing the faecal 
microbiota composition and alterations occurring in it, as the invasive sampling of different 
parts of the human intestine presents technical difficulties and ethical issues. To this end, in 
vitro and in vivo animal models provide much-needed tools to characterize the prebiotic 
effects in more detail. The effects of prebiotic fermentation on gastrointestinal microbiota and 
its functionality (e.g. SCFA production) can be easily studied in in vitro culture systems, 
whereas animal models can be used to investigate e.g. the mechanisms by which the prebiotic 
affects the immune system and colonic cells in different parts of the gut in vivo (Rumney and 
Rowland, 1992). However, while the relevance of these models to the authentic human 
gastrointestinal tract can always be questioned, valuable information on the colonic 
breakdown of complex carbohydrates and their importance in maintaining gut health has been 
obtained with the aid of  in vitro and in vivo models (Macfarlane and Macfarlane, 2007). 
1.5.1. In vitro models 
In vitro models that have been used to investigate prebiotic fermentation include pure 
cultures of bacteria, batch cultures, and different types of gastrointestinal simulators. All of 
the models use anaerobic conditions to support the growth of colonic microbes. Pure culture 
studies are the simplest way to study the ability of single microbial strains to ferment 
prebiotic compounds. Batch fermentors are usually small-scale bottle fermentors; whereas the 
different gastrointestinal simulator models are structurally more complex, containing 
sequentially connected anaerobic fermenting vessels representing different compartments of 
the human gastrointestinal tract. All batch and simulator models are kept at 37˚C, they use 
faecal material from single or several donors for inoculation and most employ artificial 
intestinal media originating from the media published by Gibson and co-workers (1988), 
mimicking the fluid of the human caecum. The simulators have similar pH set-points 
(ranging from 5.0 to 7.0) resembling those of the authentic human colon (Macfarlane et al., 
1998) and pH levels and fluid transitions are computer-controlled. Samples collected from 
these models are analyzed for their microbial composition and metabolites produced through 





1.5.1.1. Batch-type models 
Batch fermentors are the most common models with which to study prebiotic fermentation by 
colonic microbes. They are usually anaerobic, sealed bottles containing the pure cultures of a 
microbe, defined mixed microbial cultures or faecal slurry. They model a certain part of the 
gastrointestinal tract (depending on the pH) and the run-times range from 2 to 24 hours. 
Batch fermentations are useful tools in investigating the nature and amount of metabolites 
and gas produced as a result of the prebiotic fermentation but are perhaps not the best models 
with which to study microbiota composition as the accumulation of fermentation products 
(e.g. SCFAs) and the depletion of nutrients can alter the conditions and microbiota balance in 
the fermentor, thus affecting the in vivo relevance in longer simulations (Mäkivuokko and 
Nurminen, 2006; Rumney and Rowland, 1992).   
 
1.5.1.2. Gastrointestinal simulators 
The Reading simulator, introduced by Macfarlane and co-workers (1989), simulates the 
human large intestine in three connected vessels, each with a working volume of 300ml. 
Fresh feacal sample is suspended in buffer and used to inoculate each of the fermenting 
vessels, and left to reach equilibrium overnight. During the colonic transit simulation, 
medium is pumped into the system continuously and there is a continuous overflow of 
material through the three vessels. The Reading model is operated for 60 hours before the 
actual simulation with a test substrate in order to achieve microbiological steady-state 
conditions in the vessels. The test substrate is added to the model and it is run until a new 
steady-state is achieved, followed by a wash-out period. Samples are collected during and 
after the different stages and subjected to analysis. The model has been validated against 
samples obtained from GIT of sudden death victims and has been demonstrated, employing 
classical culturing techniques, to reproduce the bacterial community structure and metabolic 
activities of different parts of the colon (Macfarlane et al., 1998). By also using more modern 
molecular techniques (FISH), the composition of microbiota in the colon model has been 
shown to be very similar to that found in the original faecal inoculum (Child et al., 2006): all 
the major bacterial groups found in faeces (Bacteroides, Bifidobacterium, Lactobacillus, 
Roseburia, Ruminococci, Cl. coccoides/Eub. rectale and Atopobium groups) were also able to 
establish themselves as major groups in the colonic model, although some variation in the 
population dynamics between the three vessels was observed during the simulation run.   
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Molly and co-workers introduced a Simulator for Human Intestinal Microbiological 
Ecosystem (SHIME) (1993), which simulates the whole human gastrointestinal tract from 
stomach to colon. In this five-stage system, the first two glass vessels represent the small 
intestine and the subsequent three vessels simulate the colon and are inoculated with faecal 
suspension. Working volumes range from 300ml to as high as 1600ml (Alander et al., 1999; 
Kontula et al., 1998a). The microbiota in the SHIME model is sustained by feeding media 
into it every eight hours and the model is run for two weeks with media only before adding 
the test substance. Feeding of the substrate is continued for three weeks, followed by another 
two-week media-only period, during and after which samples are collected (Grootaert et al. 
2009). The composition of microbiota in the model has been recently assessed by denaturing 
gradient gel electrophoresis (DGGE) and HITChip analysis (Van den Abbeele et al., 2010) 
and found to, upon inoculation, display a reproducible microbial colonization and community 
development which was region specific; proximal parts of the model harboured more 
saccharolytic microbes (e.g. Bacteroides and Eubacterium spp.) whereas the population in the 
distal region was enriched in mucin-degrading microbes (e.g. Akkermansia spp.). The shift 
from the in vivo to in vitro situation was, however, characterized by a reduced diversity of the 
microbial population of the model, as the relative abundance of specific microbial groups 
were altered; members of the Bacteroides and Clostridium cluster IX were selectively 
stimulated whereas clostridial clusters IV and XIVa were reduced in the SHIME model.  
 
The EnteroMix Colon simulator (Figure 12, materials and methods section), used in this 
thesis work, was introduced by Mäkivuokko and co-workers (2005). It has four parallel units, 
all of which have four connected glass vessels, thus allowing four simulations to be run 
simultaneously using the same faecal inoculum. This simulation system has significantly 
smaller working volumes than the Reading and SHIME models (from 6ml to 12ml), requiring 
only 50ml of faecal slurry. For inoculation, fresh faecal sample is diluted and incubated for 
24 hours prior to the simulation. The colonic simulation takes two days to complete and 
during these 48 hours the transfer and feeding of the system occur semi-continuously in 
three-hour cycles. The residuals of fermented fluids and microbes are transferred between the 
vessels of the system (from V1 to V2, V3, V4, and eventually to the waste container), 
followed by the feeding of the proximal part (V1) of the model with fresh medium containing 
the test substrate. At the end of the simulation, all sample material is collected from the 
vessels and analyzed for microbiota composition and its metabolic activity (Mäkeläinen et 
al., 2007; Mäkivuokko et al., 2006). The microbiota composition and functionality of the 
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colon model has been measured against a pig model in which polydextrose fermentation was 
studied; similarities between the two models were seen in the gradual fermentation of PDX, 
the lack of bifidogenicity, and the production of SCFAs (Mäkivuokko, 2007). Further, the 
increased Bifidobacterium numbers resulting from fermentation of lactitol in the Enteromix 
model (Mäkivuokko et al., 2010) have been demonstrated in humans as well (Ouwehand et 
al. 2009), indicating that the model is able to reproduce in vitro the GIT conditions and 
prebiotic fermentation observed in vivo although an extensive analysis of the Enteromix 
microbiota composition and comparison to in vivo human colonic microbiota is still lacking. 
 
A three-stage simulator of the infant gut has also been recently developed (Cinquin et al., 
2004, 2006). In contrast to the other “free-cell culture” models described above, this model 
uses child faecal microbiota immobilized on gel polysaccharide beads, thus establishing two 
distinct bacterial populations on gel-beads and non-adherent in the liquid phase of the system. 
The free-cell suspension cultures may present stability problems, such as loss of less 
competitive bacteria during a long experiment, and this model is said to reproduce the high 
bacterial concentrations and diversity of the faeces to at least a general level, with a high 
stability in long-term experiments; and to describe more closely the microbial populations 
growing on food particles, biofilms and epithelia in the gut. One simulation experiment lasts 
for between 29 to 56 days, including colonization, stabilization, testing and re-stabilization 
periods, during which microbial and metabolite levels are analysed on several occasions. The 
model has been used in studying e.g. FOS, which was shown to differently modify the bead-
bound fraction and the non-adherent fraction of the microbiota in the model. It has also been 
modified to represent the infected child gut (Zihler et al., 2010) and was used successfully to 
investigate the long-term effects of probiotic strains and prebiotics on Salmonella infection in 
infant GIT. 
 
The TNO Intestinal Model (TIM) system is composed of two parts and was introduced by 
Minekus and co-workers (1995, 1999). The TIM-1 system simulates the stomach and small 
intestine with its eight sequentially connected glass vessels. The TIM-2 system consists of 
four glass modules in a loop representing the proximal colon. These dynamic models have 
peristaltic pumps to transfer the fluid from vessel to vessel, and there is a constant absorption 
of water and fermentation metabolites (e.g. SCFAs) through dialysis membranes. The volume 
of intestinal fluids in both models is 200ml and the simulation operation takes from one to 
three days. With the combination of TIM-1 and -2, the digestion and fermentation of 
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prebiotic compounds and other food ingredients can be modeled in the whole length of the 
human gastrointestinal tract. Also, of all the in vitro models, the continuous absorption of 
substrates perhaps enables TIM to simulate the authentic GIT the most accurately. Fresh, 
pooled feacal samples are used to prepare the standardized inoculum for the system, and this 
inoculum is either used straight away (Kovatcheva-Datchary et al., 2009) or after freeze-and-
thawing (Rajilic-Stojanovic et al., 2010). The different inoculum preparation methods seem 
to have an impact on the composition of the establishing microbiota in TIM-2, as freeze-
thawed microbiota profiles were different from those of the faecal samples of healthy adults 
(Rajilic-Stojanovic et al., 2010) whereas where the inoculum used in TIM-2 was fresh, 
microbiota resembling more closely the original faecal populations was produced 
(Kovatcheva-Datchary et al., 2009).  
1.5.2. In vivo models 
Animal models provide opportunities to study the metabolic and immunological activities of 
intestinal microbiota in more detail than in the in vitro models. Intestinal contents and also 
tissues and organs can be collected from dead animals at autopsy. Conventional, germ-free 
and human flora-associated rodent models have been used as models for the human 
gastrointestinal tract in health and disease although the gastrointestinal tract of pigs has more 
similarities with humans in terms of nutritional requirements, intestinal physiology, 
microbiota and metabolism (Fava et al., 2007) than the rodent models (Tiihonen et al., 2008). 
The effects of non-digestible oligosaccharides and fiber on gut microecology and physiology 
have been studies in rats (Bielecka et al., 2002; Dongowski et al., 2002; Henningsson et al., 
2002; Peuranen et al., 2004) and in pigs or piglets in several studies (Correa-Matos et al., 
2003; Fava et al., 2007; Krueger et al., 2002; Martinez-Puig et al., 2003). The animal models 
have clear advantages in studying the human gastrointestinal tract and microbiota over the in 
vitro models, because there are a wide range of similarities between the hosts. However, there 
are also many morphological and physiological differences between the species that may 
hinder the straight extrapolation of the results from animal models (especially with regard to 
rodent models) to humans (Henriksson, 2006). 
 
The ultimate tests for prebiotic activity have to be performed in human volunteer trials 
(Roberfroid et al., 2010). The colonic fermentation of complex carbohydrates can be studied 
with healthy volunteers using faeces or samples obtained from different parts of the GIT. The 
small intestinal fermentation can be studied, e.g., in ileostomy patients, using intubation tubes 
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positioned in the gastrointestinal tract. From samples obtained directly from the 
gastrointestinal tract, the fermentation of a substrate and the consequences on microbiota can 
be accurately measured (Englyst et al., 1996; Englyst and Cummings, 1985; Silvester et al., 
1995; Stephen et al., 1983). Also non-invasive methods with human subjects, such as breath 
hydrogen measurements (Stephen et al., 1983) or measuring SCFAs in peripheral venous 
plasma or faeces can be used (Cummings et al., 1996). However, since SCFAs are quickly 
absorbed from the colon and part is used by the colonocytes, these measurements cannot 
accurately gauge the total production of SCFAs resulting from prebiotic fermentation 
(Cummings and Englyst, 1991; Wong et al., 2006). Human clinical interventions provide the 
best model for studying the microbiota and fermentation of prebiotics but they also suffer 
from many difficulties, such as the possible low compliance of the subjects, the practical and 
ethical limitations of sampling and the high costs of intervention trials (Macfarlane and 
Macfarlane, 2007).  
 
On the whole, the study of prebiotic components is usually started with in vitro models: either 
simple pure culture or batch type fermentors can be utilized before proceeding to more 
complex in vitro simulator models and/or animal models to characterise the effects of 
prebiotics on microbiota composition and metabolic activity. Animal models can also be used 
in mechanistical studies, although the final proof of the health effects and benefits mediated 
by prebiotic consumption has to be demonstrated in controlled human intervention studies.
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2. AIMS OF THE STUDY 
 
The objectives of this series of in vitro studies were to screen new oligosaccharides for their 
prebiotic potential, compare these candidates in order to established reference prebiotics, and 
furthermore, to characterize their potential in modulating the colonic microbiota for 
subsequent product development. This was done by characterizing their effects on the colonic 
microbiota composition and functionality using in vitro models of differing complexicity.  
 
The specific aims of the study were: 
 
1. To screen a number of prebiotic candidates for their effects on the growth of selected 
probiotic, commensal and pathogenic microbes using a simple in vitro model (Studies II and 
IV). 
 
2. To characterize the properties of the most promising candidates in modulating the 
composition and metabolic activity of the microbiota using an in vitro model of the human 
large intestine (Studies I, III and V). 
 
3. To evaluate the potential of the candidates to modify the microbiota in relation to 
established reference prebiotics (Study III and V). 
 
4. To analyze the potential of a novel synbiotic product formulation in modulating the colonic 





3. MATERIALS AND METHODS  
3.1. Pure culture screening studies 
3.1.1. Prebiotic compounds 
The study compounds are listed in Table 2. Most of the oligosaccharides were chosen for the 
screening because they were either interesting new product candidates or emerging prebiotics 
that needed further testing. In addition, two commercially available prebiotics, FOS 
(Raftilose®, Beneo, Belgium) and XOS (Longlive 95P, Shandong Biotechnology co., China) 
were included into the growth assays, and glucose (α-D-glucose, Serva, Germany) was used 
as a nonselective control substrate (Vernazza et al., 2006a). Medium without any additional 
carbohydrates was used to determine the basal growth of the bacteria, and this basal growth 
was subtracted from the results. 
A 10% suspension of each compound was prepared in sterile water and the suspension was 
sterilized with ultra-violet radiation or sterile-filtered (0.2 μm Minisart, Sartorius AG, 
Göttingen, Germany), depending on the degree of polymerization of the compound, and 
stored at 4C until use.  
Results regarding the first 13 compounds in the table (from FOS to xylan) are published in 
peer reviewed journal articles. The following six compounds were also tested but the results 
have not been published. 
3.1.2. Bacterial strains and growth media 
Bacterial strains were obtained from different culture suppliers and strain collections, and 
grown in appropriate growth mediums (MRS, TSB, or Bifidomedium; Table 3) under 
anaerobic conditions. Using mediums and test tubes prepared with the Hungate boiling 
system (Hungate, 1950), anaerobic growth conditions were generated. Microbial strains were 
activated from -70°C storage in appropriate, glucose-containing medium for 24 or 48 hours at   
+37°C. After the cultivation microbes were inoculated into a fresh growth medium containing 
glucose (MRS or TSB) and incubated for another 24 hours. Then a 1% cell suspension of 
single microbes was prepared (v/v) in the test medium, which did not include any 
carbohydrates other than the tested one, and used immediately for the growth assays.   
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Table 2. Oligosaccharides tested in the studies.  
Product Description Composition Supplier
FOS
Fructo-oligosaccharide powder, dp 2-7, 
prebiotic reference
95,5% FOS dp2-6; 4,5% other dp2 
† Beneo, Belgium
Gentiobiose β-Gentiobiose powder ≥ 85 % gentiobiose (remainder primarily α anomer) Sigma (G3000)
Glucose Alpha-D-glucose powder 100% glucose Serva, Germany
GOS Galacto-oligosaccharide powder, dp 3-6
Purified from most mono- and disaccharides, 0.7% 
galactose, 1.1% glucose and 2.9% lactose
Danisco Cultures, 
France
Lactitol Lactitol powder 99 % lactitol
Danisco Sweeteners, 
UK
Panose D-Panose powder ≥ 98 % panose Sigma (P2407)
PDX
Polydextrose, Litesse® Ultra ™ 




Pullulan Pullulan powder Cosmetic grade Hayashibara, UK
Sophorose Sophorose powder ≥ 98 % sophorose Sigma (S1404)
XOS dp2* Xylo-oligosaccharide syrup, dp 2
100% XOS (7% dp1, 82% dp2, 10% dp3, 1% dp4) 
†
Lenzing AG, Austria
XOS dp2-10 Xylo-oligosaccharide powder, dp 2-10




XOS Longlive 95P  Xylo-oligosaccharide powder, dp 2-5
84% XOS (43% dp2, 30% dp3, 10% dp4, 17% 




Xylan Liquid xylan hemisuspension, dp 35-40 97% XOS dp≥5 




16% dp=2 and 11% dp≥3 GOS, 49% lactose, 13% 




oligosaccharide powder, dp 2-10 




IMO-500 Isomalto-oligosaccharide powder ≥35% IMO, no knowledge on dp distribution Genencor, USA
Meyprodor 5 Guar Gum powder
No knowledge on the specific structure of the 
product
Genencor, USA
Meyprodor 30 Guar Gum powder
No knowledge on the specific structure of the 
product
Genencor, USA
Sun Fiber Partial hydrolysate of Guar Gum, powder
No knowledge on the specific structure of the 
product
Sun Fiber, Japan
*; dp = degree of polymerisation














Bacteroides fragilis ATCC 
a




Bacteroides vulgatus DSM 
b
 1447 Meat medium MRS-
Bifidobacterium adolescentis DSM 20083 Medium 58 
2
MRS-
Bifidobacterium breve Bb-03 
c
Medium 58 MRS-
Bifidobacterium infantis DSM 20088 Medium 58 MRS-
Bifidobacterium lactis Bi-07 
c
Medium 58 MRS-
Bifidobacterium lactis Bl-04 
c
Medium 58 MRS-
Bifidobacterium lactis 420 
c
Medium 58 MRS-
Bifidobacterium lactis DN-173 010 
d
Medium 58 MRS-






Bifidobacterium longum 913, Wisby
 c
Medium 58 MRS-
Bifidobacterium longum KC-1 
c
Medium 58 MRS-
Bifidobacterium longum DSM 20219 Medium 58 MRS-
Clostridium difficile* ATCC 9689 Meat medium MRS-




Eubacterium biforme* DSM 3989 MRS+ 
4
MRS-
Eubacterium limosum ATCC 8486 Meat medium MRS-
Escherichia coli EHEC 0157:H7 
f
TSB+ TSB-
Lactobacillus acidophilus NCFM 
c
MRS+ MRS-






Lactobacillus rhamnosus HN001 
c
MRS+ MRS-
Salmonella typhimurium EELA 4185/96 
g
TSB+ TSB-
Staphylococcus aureus  sp. aureus* ATCC 10990 TSB+ TSB-






* Results of these strains are not presented as the growth on glucose was negligible
a) American Type Culture Collection, USA; b) Deutsche Sammlung von Mikroorganismen und Zellkulturen
c) Danisco; d) Danone e) Christian Hansen; f) EHEC 0157:H7 The German Resourse Centre for Biological material
g) Veterinary and Food Research Agency, Finland; h) Culture Collection, University of Göteborg, Sweden 
1) DifcoTM Cooked meat medium; Beckton, Dickinson and Company, USA; 2) Bifidomedium, DSMZ
3) Tryptic soy broth (with glucose); LAB M, UK; 4) de Man, Rogosa and Sharpe medium with glucose 
(recipe: MRS broth, LAB M, UK); 5) de Man, Rogosa and Sharpe medium without glucose
6) BactoTM Tryptic soy broth without dextrose; Beckton, Dickinson and Company, USA  
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3.1.3. Measurement of the bacterial growth intensity 
The growth of the bacterial strains on different carbohydrate substrates was measured with an 
automatic Bioscreen® C system (Labsystems, Helsinki, Finland) connected with a PC 
equipped with a Biolink® software package (Labsystems). The system recorded kinetic 
changes in the absorbance (600nm) of liquid samples in a 100-well plate and the growth rates 
of different oligo- and polysaccharide and microbe combinations were determined from this 
data. 
The Bioscreen system was kept in an anaerobic hood (80% N2, 10% CO2 and 10% H2) and all 
bacterial strains were cultured in anaerobic conditions and media. Test substrate solutions 
(10%) or glucose (10%) were added to each well of the plate (20µl), and the wells were filled 
with the diluted cell suspension (180μl) of a single bacterial strain (OD 0.2-0.6). Thus, the 
final concentration of the carbohydrate substrate in each well was 1% (w/v). For control wells 
with medium without added carbohydrates, 20µl of sterile water and 180μl of microbial 
suspension were added. Anaerobic conditions and techniques were used during the growth 
assay. Bacterial strains were incubated at 37ºC for 24 hours and the optical density of the 
samples was measured at 600nm once every 30 minutes. Plates were mixed for 10 seconds 
prior to measurement. At least two sets of experiments were conducted on each strain-and- 
carbohydrate combination with five replications. 
The bacterial growth was determined as the area under the growth curve (OD600 x min) 
obtained from the Bioscreen® data. As previously described, the growth in the blank control 
medium (MRS or TSB without added carbohydrates) was subtracted from results as baseline 
growth (Jaskari et al., 1998). The relative growth rate of a bacterium was obtained by 
comparing the area under the growth curve of each strain and prebiotic combination to the 
growth of the same bacterial strain in glucose, the positive control, and converted to relative 
growth rates (Crittenden et al., 2002). 
3.2. Colonic fermentation studies 
3.2.1. Colon simulator 
The semi-continuous Enteromix® human colon simulator has been used in studying potential 
prebiotic compounds and the structure and function of the system has been previously 
described in detail (Mäkivuokko et al., 2005; Mäkivuokko et al., 2006). The simulator 
consisted of four parallel units, each of which was comprised of four sequentially connected 
glass vessels, V1 to V4. The conditions in the vessels were adjusted to represent the different 
 42 
compartments of the human colon: V1 represented the ascending colon, V2 the transverse 
colon, V3 the descending colon, V4 the end of descending colon and sigmoid/rectal area. The 
set pH levels in the simulator vessels (5.5, 6.0, 6.5 and 7.0) were similar to those measured in 
different parts of the human colon (Cummings and Macfarlane, 1991; Macfarlane et al., 
1992) and were adjusted with gaseous ammonia when the pH dropped below the target level. 
The volumes of microbial slurry in the vessels increased from the ascending to the distal end 
(6, 8, 9, and 12ml), mimicking the reduced flow. The simulator was kept anaerobic at 37°C in 
a thermostatic room. All run parameters, including pH control and gas and liquid transitions, 




5.5 6.0 6.5 7.0 
4°C 
4°C 
3ml 5ml 7ml 9ml 
  Medium 
Waste   V2  V3 V4 
  
N 2 N 2 N 2 N 2 
  NH3 
 
Figure 12. A single unit of the EnteroMix™ human colon simulator, consisting of four 
connected glass vessels (modified picture from Mäkivuokko et al., 2006). The volumes and 
pH of the different vessels are shown below the figure, V1 = 1
st
 vessel, V2 = 2
nd
 vessel, V3 = 
3
rd
 vessel, and V4 = 4
th
 vessel, N2 = nitrogen gas, NH3 = ammonium gas. 
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3.2.2. Simulator medium and test substrates 
Synthetic ileal fluid, originally described by Gibson et al. (1988), was used as the basic 
simulator medium in the colon model. The medium contained the following constituents (g/l) 
in distilled water: starch 5.0; peptone 0.05; tryptone 5.0; yeast extract 5.0; NaCl 4.5; KCl 4.5; 
mucine (porcine gastric type III, Sigma Chemicals Co., St.Louis, USA) 4.0; casein 3.0; pectin 
(citrus) 2.0; xylan (oatspelt) 2.0; arabinogalactan (larch wood) 2.0; NaHCO3 1.5; MgSO4 
1.25; guar gum 1.0; inulin 1.0; cysteine 0.8; KH2PO4 0.5; K2HPO4 0.5; bile salts no.3 0.4; 
CaCl2 x 6 H2O 0.15; FeSO4 x 7 H2O 0.005; hemin 0.05; and Tween 80 1.0. Tested prebiotic 
compounds were suspended into this medium (2% concentration, w/v), and no other 
carbohydrates, in addition to the ones in the basic medium, were added to the baseline 
simulations. 
3.2.3. Faecal inocula  
Faecal samples were obtained from healthy human volunteers (aged between 4 and 85 years 
old; Study I n=4; Study II n=1; Study III n=4; and Study V n=7) and the faeces of a single 
donor were used to run a set of four parallel simulations. Fresh faecal material was diluted 
with the simulator media and filtered through a 0.3 mm metal mesh, after which it was 
incubated anaerobically for 24 hours at 37°C (Mäkivuokko et al., 2005). In the experiments 
with XOS (Study III), it was noticed in the first three simulation runs that the levels of 
Bifidobacterium lactis varied significantly between the donors and thus, in the last four 
simulation sets, the inoculum was spiked with B. lactis Bi-07 (Danisco Cultures, Niebüll, 
Germany) to ensure a basal level of this species. The amount of B. lactis added to the 
inoculum was, on average, 2.0 x 10
7
 CFU/ml (± 6.4 x 10
6
), which accounted for 
approximately 20% of the average B. lactis numbers measured in the faecal matter used in 
Study III (9.6 x 10
7
 ± 4.4 x 10
7 
CFU/ml). All of the test substrates were simulated once with 
non-spiked inoculum and twice with spiked inoculum and so the effect of additional B. lactis 
on the results was equal to all of the tested compounds. In other simulation experiments with 
other candidate prebiotics (Studies I, II and V), no spiking was required. In the synbiotic 
simulation experiments (Study V), probiotics were added to the medium in some of the 
assays (probiotic and synbiotic) but not in all (control and prebiotic).  
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3.2.4. Operating the simulator  
Prior to inoculation, all of the tubing and vessels of the simulator were flushed with nitrogen 
gas for one hour and filled to pre-set levels (3, 5, 7, and 9ml respectively) with anaerobic 
NaCl-solution. The preconditioned faecal sample from a single donor was injected 
anaerobically into the V1 vessel of all four simulation units, mixed well, and part of the 
diluted inoculum was transferred to vessel V2. The transfer procedure was repeated between 
vessels V2 and V3, V3 and V4 and eventually between V4 and the waste container. The final 
volumes in vessels V1, V2, V3 and V4 were again 3, 5, 7, and 9ml respectively. Three hours 
after the initiation of the simulation experiments, fresh medium was pumped into the V1 
vessel. The medium was fermented in the first vessel for three hours and then 3ml of the 
fermented fluid was transferred to the V2 vessel by gas pressure. The transitions of the 
medium and the feeding of fresh media occurred in the same manner at three-hour intervals 
and the fermented medium residuals moved from vessel to vessel and eventually into the 
waste container. Simulation was continued for 48 hours, after which the samples were 
collected. At this point the volumes in vessels V1, V2, V3 and V4 were 6, 8, 10, and 12ml 
respectively. 
3.2.5. Analysis of microbial numbers 
Total bacterial numbers from the simulator samples were determined by flow cytometry as 
previously described (Apajalahti et al., 2002). Briefly, the bacterial samples for flow 
cytometry analysis were fixed with 4% formaldehyde immediately after the simulation and 
stored at 4°C until analysis. The microbes were stained with a fluorescent, nucleic acid 
binding dye, SYTO 24 (Molecular probes, Leiden, The Netherlands), prior to counting them 
with the FACSCalibur system (BD Biosciences, San Jose, CA, USA). 
Quantitative PCR (qPCR) was utilized to determine Bifidobacterium, Lactobacillus, 
Bacteroides-Prevotella-Porphyromonas and Clostridium histolyticum (clusters I and II) 
group densities (Study I: only Bifidobacterium). Also Bifidobacterium longum (studies I and 
III) and Bifidobacterium lactis (Studies II, III and V) species densities were enumerated from 
simulator samples. Samples for the qPCR analyses were harvested using centrifugation at 
48000 x g for 15 minutes; the pellets were stored at –70°C until DNA extraction. Microbes 
were first lysed with lysozyme and then with bead beating, DNA was extracted with 
chloroform-isoamylalcohol treatment as described previously (Apajalahti et al., 1998) and 
DNA was purified using a commercial kit (Genomic DNA extraction kit, Qiagen, Hilden, 
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Germany). Oligonucleotide primers (Thermo Biosciences, Ulm, Germany or MedProbe, 
Lund, Sweden) and a probe for Bifidobacterium species detection (Applied Biosystems, 
Warrington, UK) were used. The assays were performed with ABI Prism 7000, 7300 or 
7500 FAST Sequence Detection System (Applied Biosystems, Foster City, CA), using 
optimized concentrations of mastermix ingredients and PCR cycle conditions (Table 4).  
The amplification mixture (25µl) contained SYBR Green® or TaqMan® Mastermixes 
(Applied Biosystems, Warrington, UK), primers in optimized concentrations, H2O and 1ng 
DNA template isolated from the microbial samples. The temperature profile for the annealing 
and amplification cycle consisted usually of ten minutes at 95˚C, followed by 30-40 cycles of 
15 seconds at 95˚C, 30 seconds at 55-65˚C, and 30 seconds at 72˚C, with the exception of the 
PDX-xylitol study where 40 cycles of 15 seconds at 95˚C and one minute at 60-64˚C were 
used (Table 4). 
3.2.6. Analysis of metabolites  
Chromatographic analysis of volatile fatty acids and lactic acid was performed as previously 
described with pivalic acid as an internal standard (Ouwehand et al., 2009). Briefly, samples 
collected from the simulator were mixed with pivalic acid, water and saturated oxalic acid 
then centrifuged and incubated at 4°C. The supernatant was analyzed by gas chromatography 
using a flame ionization detector and helium as the carrier gas. Concentrations of acetic, 
propionic, butyric, isobutyric, valeric, isovaleric, 2-methylbutyric and lactic acids were 
determined. 
Biogenic amines were analyzed as dansyl derivates by reversed phase high-performance 
liquid chromatography (HPLC), using a method by Saarinen (2002). Heptylamine was used 
as an internal standard and the biogenic amines were extracted with perchloric acid. Biogenic 
amines were derivatised with dansyl chloride, separated on a reverse phase HPLC column 
and detected with a fluorescent detector. The concentrations of methylamine, ethylamine, 
tryptamine, 2-methylbutylamine, putrescine, cadaverine, histamine, tyramine, spermidine, 
and spermine were determined. 
Xylo-oligosaccharides in the fermentation fluids were determined by high pH ion exchange 
chromatography with pulsed electrochemical detection, using a Carbo Pak-PA1 separation 
column and a mixture of water and 0.2 M NaOH as eluent. Fructo-oligosaccharides were 
analyzed as total fructose after acid hydrolysis. The acid hydrolysis was conducted by 
incubating the sample in sulphuric acid and thereafter fructose was determined by high pH 
ion exchange chromatography as described (Bach Knudsen, 1997). Polydextrose 
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concentrations were measured using a HPLC method described previously (Craig et al., 
2000); and xylitol concentrations were determined by a commercial enzymatic colorimetric 
method (Boehringer Mannheim/R-Biopharm, Darmstadt, Germany). GOS or panose 
concentrations were not analysed from the samples as methods for their determination were 
not available at the time. 
3.2.7. Statistical analysis 
Data are reported as the mean values of the results from all the vessels of a simulator unit 
(from V1 to V4) and replicates (n = 3 or 4 for the test compounds and n = 4-8 for baseline 
simulations) and the standard error of the mean (SEM). The statistical analysis was 
performed using SPSS software (SPSS, Inc., Chicago, Ill., USA, 14.0 and16.0 versions). Data 
were assessed using ANOVA and t-tests or Tukey‟s multiple comparison tests to compare 
results from baseline simulations with the test substrates, and also to compare results between 
the commercial prebiotics and other substrates. The differences among the means were 
considered significant when P<0.05. Spearman correlation coefficiencies were also 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1. Pure culture screening studies 
The growth of tested bacterial strains in pure cultures on different test substrates is presented in 
Table 5. In Study II, panose and sophorose were tested in pure cultures with ten microbial strains 
due to the limited availability of the products. In Study IV, a range of probiotic, commensal and 
pathogenic microbial strains (n=23) were used. 
 
4.2. Colon simulator studies  
The characterization of interesting prebiotic candidates was continued with the in vitro colon 
simulator model with the aim of mimicking prebiotic fermentation in the human large intestine by 
complex microbiota. In these studies (I, II, III and V), fermentation of XOS compounds (dp2, dp2-
10 and Longlive), xylan, FOS, panose, GOS and PDX (all 2% w/v) were investigated. Furthermore, 
in Study I, PDX and xylitol were a tested combination (PDX 1% + xylitol 1%, w/v); and in Study 
V, PDX and GOS were analysed together with probiotic B. lactis (in synbiotic GOS+PDX+B. 
lactis; PDX 1% + GOS 1%, w/v). The results from all four vessels of the simulator model were 
combined and thus one simulator unit was treated as one entity in order to make results more 
comprehensible. Moreover, results regarding the metabolic activity of the microbiota were also 
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4.2.1. Microbiota composition 
 
Results regarding the investigated bacterial groups from all studies (I, II, III and V) are presented in 
Table 6 as mean values (log10 ± SEM) per ml of fermentation fluids from all four vessels (V1 to 
V4). Bifidobacteria was the group most commonly affected by various prebiotics but other 
measured bacterial groups, namely Lactobacillus, Bacteroides-Prevotella-Porphyromonas and 
Clostridium histolyticum (clusters I and II), were also modified by different substrates. The species 
densities of either B. lactis and/or B. longum were also investigated in all studies; in Study III, XOS 
enhanced the growth of B. lactis significantly more than FOS (P<0.05 for XOS Longlive and 
P<0.01 for XOS dp2-10), whereas FOS increased the growth of B. longum more than XOS 
compounds (P<0.05 for XOS dp2-10 and xylan, and P<0.01 for XOS Longlive).  
 
In Study V the different synbiotics were further compared to the constituting pre- and probiotic 
components. The PDX+B. lactis combination resulted in higher numbers of total microbes (P<0.01) 
and greater production of acetate (P<0.01) and propionate (P<0.01) in comparison to the probiotic 
B. lactis, whereas, in relation to the prebiotic component, increased levels of B. lactis (P<0.01) and 
Bifidobacterium species (P<0.05), as well as and acetate and total biogenic amines, were measured. 
Synbiotic GOS+B. Lactis, in comparison to the probiotic, had significantly more effects on the 
levels of total Bifidobacterium and Bacteroides-Prevotella-Porphyromonas species and several 
metabolites; acetate (P<0.001) and butyrate (P<0.001) concentrations were increased while the total 
levels of amines (P<0.001) and isovaleric acid (P<0.01) were decreased. In comparison to prebiotic 
GOS, the synbiotic increased the numbers of B. lactis (P<0.05) while concomitantly decreasing 
Bacteroides-Prevotella-Porphyromonas (P<0.05) group members. An increased trend of 
Bifidobacterium (P=0.057) and decreased Lactobacillus (P=0.06) groups were also measured. When 
PDX was added to the synbiotic GOS+B. lactis, further modifications on the microbial metabolism 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.2. Metabolic activity of the microbiota 
The metabolic functionality of the microbes in the whole length of the colon model was modified 
very similarly by most of the prebiotic substrates; increased production of different SCFAs was 
measured with a concomitant decrease in the BCFA (Table 7). The total concentrations of measured 
biogenic amines remained mainly unaffected, as only GOS (and GOS+B. lactis) significantly 
decreased the production of these metabolites and xylitol increased it. Individual biogenic amine 
concentrations were affected by a few of the compounds; some compounds increased the 
production of amines while others decreased it, e.g. tyramine production was decreased by panose 
and XOS dp2 fermentation, but increased in XOS Longlive and FOS simulations. 
Significant correlations between some metabolite concentrations and bacterial numbers were 
observed in the combined data set from all simulations. SCFA acetate and butyrate and lactic acid 
levels were positively correlated with Bifidobacterium group numbers, whereas an inverse 
correlation between bifidobacteria and propionate was found. On the contrary, propionate 
concentrations were positively correlated with Bacteroides-Prevotella-Porphyromonas and Cl. 
histolyticum group numbers. Total biogenic amines and all BCFAs were also inversely correlated 
with bifidobacteria, whereas a positive correlation was found between total amines and 
Lactobacillus. Bacteroides-Prevotella-Porphyromonas group numbers were also positively 
correlated with total amines and all BCFAs while Cl. histolyticum group levels correlated 
negatively with acetate and butyrate.  
Table 7. (Continued on next page) The concentration of metabolites after the fermentation of prebiotic compounds in 
the colon model (mean ± SEM). The concentrations of biogenic amines are given for total amount of measured amines 
and individually for the most abundant and significantly altered amines. The statistical difference from the respective 
baseline simulations is marked with stars: * P < 0.05; ** P < 0.01; *** P < 0.001. 
Study I
Acetate 24.4 ± 1.7 62.5 ± 4.7 *** 13.1 ± 2.6 ** 25.6 ± 3.3
Propionate 7.8 ± 0.5 18.5 ± 2.1 *** 8.8 ± 0.8 14.2 ± 1.5 ***
Butyrate 8.7 ± 0.6 21.7 ± 1.4 *** 56.2 ± 5.6 *** 46.0 ± 5.6 ***
Lactic acid 0 ± 0 0.176 ± 0.1704 0.76875 ± 0.4151 0.284 ± 0.196
Isobutyric acid 0.9 ± 0.1 0.6 ± 0.1 ** 0.6 ± 0.2 0.5 ± 0.1 ***
2-methylbutyric acid 0.5 ± 0.1 0.2 ± 0.1 *** 0.2 ± 0.1 *** 0.2 ± 0.0 ***
Isovaleric acid 0.9 ± 0.1 0.4 ± 0.1 *** 0.2 ± 0.1 *** 0.3 ± 0.1 ***
Valeric acid 1.4 ± 0.2 1.3 ± 0.2 1.5 ± 0.3 1.3 ± 0.3
Methylamine 28.8 ± 7.9 30.2 ± 4.1 29.2 ± 3.5 22.5 ± 4.6
Putrescine 27.6 ± 10.2 19.4 ± 6.8 44.5 ± 10.9 80.6 ± 17.9 *
Piperidine 9.2 ± 4.8 3.2 ± 1.4 3.0 ± 1.3 4.8 ± 1.6
Cadaverine 205.5 ± 29.9 178.2 ± 23.7 264.4 ± 25.1 * 258.0 ± 33.6
Histamine 8.3 ± 1.8 3.9 ± 1.4 ** 5.7 ± 1.6 * 6.2 ± 1.7 *
Tyramine 17.9 ± 2.3 15.5 ± 2.1 ** 17.1 ± 2.2 16.8 ± 2.1


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































When individual vessels of the colon model were investigated separately, differences in the 
production rate of SCFA and BCFA were observed in different parts of the colon model (Table 8). 
GOS, panose, FOS, xylitol and PDX all initiated the production of SCFA as early as in the proximal 
vessel V1 of the colonic model, where significantly increased levels of acetate and/or 
butyrate/propionate were measured. Fermentation of XOS compounds led to significantly increased 
SCFA levels in the middle and distal parts of the colon model, as increased concentrations of 
butyrate and/or acetate were measured from vessel V2 onwards. The production of proteolytic 
metabolites (BCFA and/or biogenic amines) were already depressed by GOS, panose and xylitol as 
early as in the proximal (V1) part, whereas PDX-containing compounds and XOS dp2 decreased  
BCFA production also distally (V4), in the colon model. Probiotic B. lactis did not affect the 
metabolism of microbiota in individual vessels although the synbiotic PDX+B. lactis and GOS+B. 
lactis had similar effects on metabolite production as the prebiotic components alone had. 
Furthermore, PDX(1%)+GOS(1%)+B. lactis showed the combined effects of the two synbiotic 
products from vessel V1 onwards.   
Table 8. Significantly (P<0.05 or more) altered levels of most abundant metabolites in different 
vessels of the colon simulator after 48-hr fermentation with prebiotic, probiotic and synbiotic 
substrates. Bold capital letters indicate increased production, whereas small letters in italics indicate 
the decreased production of that substrate in the specific vessel. 
V1 V2 V3 V4
PDX A,B* A,P,B,bcfa A,P,B,bcfa A,P,B,bcfa
Xylitol A,B,bcfa B,bcfa B B
PDX+xylitol P,B,bcfa P,B,bcfa P,B,bcfa
Panose A,bcfa A,B,bcfa A,B,bcfa A,B
XOS dp2 B, bcfa A,B,bcfa A,B,bcfa
XOS dp2-10 B,bcfa B B
xylan BA
XOS Longlive A,B,bcfa A,B A,B,P
FOS P A, bcfa A, bcfa A
GOS A,bcfa,ba A,B,bcfa A,B,bcfa,ba A,B
B.lactis  Bi-07
PDX+B.lactis A A, P, B A, P, B,bcfa A, P,bcfa
GOS+B.lactis A,P,ba A,B,bcfa A,B,bcfa A,B
PDX+GOS+B.lactis A A,P,B,bcfa A,P,B,bcfa A,P,B,bcfa
* A=acetate; P=propionate, B=butyrate; BA=biogenic amines;
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4.2.3. Degradation of tested compounds in the colonic model 
Slow degradation of PDX and a faster degradation of xylitol were observed (Study I). Part of the 
added PDX was still left in the distal colon, whereas xylitol was degraded by the microbes in the 
proximal and middle parts of the model. The degradation of both PDX and xylitol was also similar 
in the combination simulations, where these carbohydrates were present in lower concentrations. 
Oligosaccharides XOS and FOS were more rapidly consumed by the microbes in the simulated 
colon (Study III) as the concentrations of residual oligosaccharides were very low in the proximal 
part of the model and non-measurable in the distal part (Figure13). 
 
 
Figure 13. The concentrations of A) 
PDX and xylitol, B) XOS and C) FOS 
(as free fructose) in simulator vessels 






The study and invasive sampling of different parts of the human GIT presents numerous 
methodological and ethical problems and therefore several in vitro models of the human colon have 
been introduced (Mäkivuokko and Nurminen, 2006; Cinquin et al., 2004, 2006). In vitro models 
provide the means to investigate the microbiota in different parts of the colon and analyse bacterial 
metabolites in more detail as they are absorbed and utilized by the host in vivo. These models do 
suffer from a few limitations, such as the absence of host epithelial and immune cells and also the 
inoculation with faecal material, which represents the microbiota of the distal part of the human 
colon and which differs significantly from the mucosa- and biofilm-associated bacterial 
communities (Zoetendal et al., 2002; Cinquin et al., 2004, 2006). However, by varying the 
parameters that influence the fermentation processes (pH, dilution factor, and nutrient availability), 
the prevailing conditions in the simulator can be made to resemble the different parts of the colon 
(Macfarlane et al., 1998; Egert et al., 2006). In addition, the microbes in faeces are mostly of 
luminal origin and it is thus reasonable to assume that most of these microbes in closest proximity 
to the food bolus will carry out the fermentation of fiber and prebiotics in the colon (Rumney and 
Rowland, 1992). Therefore, in vitro methods have been videly used in studying the processes that 
occur in the lumen of the colon during the fermentation of a prebiotic (Egert et al., 2006; Rumney 
and Rowland, 1992); the Enteromix colon simulator has also been used previously in modelling 
human colonic microbiota and its functionality (Mäkivuokko et al., 2005, 2006, 2007) and was also 
utilised in this thesis work in the characterization of prebiotic candidate compounds, their 
fermentation properties and their potential in synbiotic combinations.  
 
Prior to the colon simulator, a simple in vitro screening tool (Bioscreen®) was used to scan through 
a group of candidate compounds. Fermentation of prebiotics was tested with a range of probiotic, 
commensal and pathogenic bacterial strains in pure cultures and, according to these results, a few 
interesting compounds were selected for further characterization with the colon model. It was 
demonstrated that XOS compounds with varying degree of polymerization were well fermented by 
Bifidobacterium lactis strains; B. adolescentis was the only other species to metabolize XOS to a 
great degree. In line with previously reported studies (Jaskari et al., 1998; Kontula et al., 1998b), 
lactobacilli and most commensal and pathogenic strains were not able to metabolize XOS 
efficiently, with the exception of Bacteroides strains that exhibited some growth (Crittenden et al., 
2002). In previous studies, Bacteroides strains have, however, been shown to mainly utilize the 
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monosaccharide (xylose) fraction in the products (Jaskari et al., 1998). Similarly to XOS, panose, 
sophorose and lactitol were only fermented by a few probiotic strains in pure cultures; lactitol by 
probiotic lactobacilli and B. infantis, panose by two B. lactis and L. bulgaricus strains and 
sophorose by one probiotic B. lactis and two probiotic Lactobacillus strains. Previously, the 
fermentation of panose by Bifidobacterium spp., Bacteroides fragilis, Ent. faecalis and Cl. 
ramosum, but not with a range of other bacteria in pure cultures (n=37), has been reported 
(Kohmoto et al., 1988), as well as the utilization of lactitol by Lactobacillus strains (Kontula et al., 
1999). On the other hand, the established prebiotics, FOS and GOS, were fermented by a wider 
range of tested microbes: Bifidobacterium, Lactobacillus, and even some potentially pathogenic 
microbes (e.g. E. coli, Cl. perfringens and Staph. epidermis), were able to utilize them. Previous 
studies have also reported the non-selectivity of FOS in pure culture studies, where FOS enhanced 
not only the members of genera generally considered beneficial, but also other intestinal microbes 
such as Bacteroides spp, Clostridium spp, Enterobacteria and Eubacterium spp. (Hartemink et al., 
1997; Jaskari et al., 1998). The prebiotic candidates, gentiobiose and IMO-500, were also fermented 
by a range of the tested microbial strains, whereas polydextrose, xylan and pullulan were only 
limitedly fermented in pure cultures, which could be due to the long-chained and/or highly 
branched structure of these compounds making it difficult for a single microbial strain to hydrolyse 
them (Crittenden et al., 2002). A few of the products were omitted from published results as the 
composition of the product made the interpretation of the results difficult: the poor growth of 
bacterial strains with guar gum samples was probably due to the high viscosity of the compounds, 
and the commercial GOS (Bi
2
muno) contained a large amount of galactose, glucose and lactose 
(more than 70% in the commercial compound) which were difficult to separate from the product 
and adversely affected the growth rates. Hydrothermolytically produced HT XOS also inhibited the 
growth of all tested microbes, although it had similar structure to XOS dp2-10, and so the 
compound contained some unknown substrates, deriving from the production process, which had 
anti-microbial properties. 
 
Pure culture studies can assist in understanding the fermentative capacity of individual strains and 
the mechanisms of polysaccharide break-down within the microbiota (Crittenden et al., 2002). 
However, as fermentation in the colon is a complex process involving various bacterial enzymes 
(endo- and exosaccharidases) and cross-feeding between micro-organisms (Jaskari et al., 1998), it is 
thus evident that studies done with single microbes in pure cultures do not wholly describe prebiotic 
fermentation in a complex microbial ecosystem in vivo in the large intestine (Roberfroid, 2007). 
FOS and GOS have been demonstrated to quite selectively enhance bifidobacteria in the presence of 
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complex gut microbiota in several studies (Macfarlane et al., 2008; Rycroft et al., 2001c; Wang and 
Gibson, 1993) even though in pure culture experiments they were fermented by a variety of tested 
microbial strains (Hartemink et al., 1997; Jaskari et al., 1998; Kneifel et al., 2000). This probably 
relates to the fact that although several bacterial strains may be able to utilize the substrate in pure 
cultures, some of the microbes (such as bifidobacteria) have the high-affinity oligosaccharide 
transporters and multiple glycolytic enzymes specific for oligosaccharides which enable them to 
efficiently utilise non-digestible carbohydrates in the competitive environment of the gut (Schell et 
al., 2002; van den Broek et al., 2008; Vernazza et al., 2006a). It has been demonstrated that when 
bifidobacteria (B. bifidum) and lactobacilli (L. plantarum) are co-cultured with pathogens, e.g. 
Escerichia coli and Campylobacter jejuni, which are potentially able to utilize the prebiotic in pure 
culture, the probiotic microbe inhibits the growth of the pathogenic microbes and lowers the pH as a 
result of the prebiotic fermentation, thus making conditions harder for the potential pathogen to 
succeed in (Fooks and Gibson, 2002, 2003; Gibson and Wang, 1994b). Consequently, the critical 
issue in the fermentation of oligosaccharides in the gut is how they are fermented in the presence of 
complex microbiota. Therefore, the most interesting candidates were chosen after the preliminary 
screening assays, namely XOS compounds, xylan, panose, FOS, PDX and GOS, for further 
characterization in the simulated human colon inoculated with human faecal microbiota. Athough 
sophorose performed well in the screening study, it was not analysed in the colon model as such 
data on sophorose fermentation already exists (Sanz et al., 2005). The potential of lactitol was also 
recognised in the pure culture experiments, after which the efficacy of lactitol and L. acidophilus 
NCFM has been investigated using the Enteromix in vitro colon model (Mäkivuokko et al., 2010) 
and in a human clinical trial (Ouwehand et al., 2009). The results indicate that this synbiotic 
combination could confer beneficial effects on the composition of the microbiota, its metabolic 
activity (production of butyrate) and immunity, especially with elderly subjects.  
 
In the colon simulator model, rapid fermentation of commercial XOS Longlive and hardwood-
derived XOS dp2 and dp2-10 compounds led to the enhanced growth of bifidobacteria. In the same 
study (Study III), FOS was shown to significantly enhance Bifidobacterium growth, and in contrast 
to previously published results from in vitro colonic fermentation studies (Sghir et al., 1998; Zampa 
et al., 2004), decreased Lactobacillus growth was also measured. Bacteroides-Prevotella-
Porphyromonas and Cl. histolyticum groups remained unchanged during XOS and FOS 
fermentation. Interestingly, XOS and FOS seemed to target different species among the 
bifidobacterial population, as XOS (two of the oligosaccharides with larger dp distribution) 
significantly enhanced the growth of B. lactis, whereas FOS enhanced the B. longum species, and 
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the numbers of these species were significantly different between the substrates. In pure cultures, 
FOS has been shown to be fermented by B. longum strains and XOS by B. lactis strains in both this 
and previous studies (Crittenden et al., 2002; Hopkins et al., 1998). These in vitro studies, however, 
demonstrated the possibility of prebiotics targeting different species of Bifidobacterium in the 
mixed faecal flora. These results warrant further investigations in the future on the synbiotic 
efficacy of these combinations. 
Xylan, a larger polysaccharide composed of xylose units, also increased the total Bifidobacterium 
numbers but it did not, however, specifically enhance the growth of either the B. lactis or B. longum 
species. The other investigated microbial groups also remained unchanged.  
Similarly to XOS, panose fermentation (Study II) significantly enhanced the growth of total 
bifidobacteria and B. lactis species but also influenced other investigated bacteria: the significantly 
reduced growth of Bacteroides and a decreased trend of Clostridium histolyticum group growth was 
observed. These studies provided the first data on pure panose fermentation in mixed human faecal 
microbiota, as only pure culture studies have been previously performed on this substrate (Kohmoto 
et al. 1988). 
The fermentation of PDX was studied in two of the experiments; in Study I it was analysed together 
with xylitol and in Study V together with GOS and probiotic B. lactis Bi-07. In both of the studies, 
a sustained assimilation of PDX was seen as its concentration gradually decreased in the simulator 
vessels. The complex structure of the PDX molecule was not easily utilized and the molecule was 
degraded only by a consortium of microbes, since in pure cultures it was very poorly fermented by 
single bacterial strains. The sustained fermentation of PDX has been demonstrated in humans as 
well (Hengst et al., 2008) and might benefit the health of the colon by increasing saccharolytic-type 
fermentation distally. Previously, mixed results have been obtained on the bifidogenicity of PDX 
(Probert et al., 2004, Mäkivuokko et al., 2005; Tiihonen et al., 2008) and in this study PDX did not 
affect Bifidobacterium, Lactobacillus or Bacteroides-Prevotella-Porphyromonas group numbers in 
the colonic model, but increased the growth of Clostridium histolyticum group (Study V). This 
group contains potentially pathogenic clostridial strains (Cl. difficile and Cl. perfringens) and 
therefore the effects of PDX on the microbiota composition will have to be investigated in more 
detail in the future. The contadictory results on the bifidogenicity of PDX (as well as other prebiotic 
substrates) may derive from the fact that an increase in Bifidobacterium numbers as a result of 
successful probiotic or prebiotic intervention can be detected only if the initial levels of these 
microbes are low; high initial levels tend to remain stable (Kolida et al., 2007; Ouwehand et al., 
2006; Rao, 1999; Tuohy et al., 2005). In these simulator studies the levels of bifidobacteria were at 
moderate levels, as the numbers of total bifidobacteria ranged from 1x10
8
 to 5 x10
8
 copies / ml of 
 60 
faecal slurry in the simulator vessels. Previously, as reported by Tiihonen and others (2008), low 
levels of bifidobacteria (1x10
7 
CFU / g faeces) have been increased after PDX supplementation. 
Nevertheless, in the same simulator experiments, GOS fermentation increased Bifidobacterium 
levels by one log. GOS also significantly increased B. lactis strain densities but other measured 
microbial groups remained unchanged, even though GOS was generally well-fermented in the pure 
culture experiments by various microbes. This is in agreement with numerous studies where the 
bifidogenicity has been demonstrated  in vitro (Palframan et al., 2002; Rabiu et al., 2001; Sharp et 
al., 2001), in animal models (Djouzi and Andrieux, 1997; Holma et al., 2002; Tzortzis et al., 2005) 
and in humans (Depeint et al., 2008; Vulevic et al., 2008).  
No conclusion on the effects of xylitol on the gut microbiota can be drawn, based on these in vitro 
studies, as only total numbers of Bifidobacterium species and B. longum were measured in Study I 
and those remained unchanged during xylitol fermentation, also when xylitol was combined with 
PDX. 
 
Unlike prebiotics, synbiotics have not received much attention since their introduction in 1995. 
Synbiotic products can be combinations of any pro- and prebiotics but the effectiveness of any 
combination has been questioned recently (Saulnier et al., 2007, 2008; de Vrese and Schrezenmeir, 
2008); the issue seems to be whether the prebiotic should be selective for the probiotic component 
and enable them to complement each other in such a way that additional benefits are mediated in 
comparison with the constituting pro- and prebiotic components. In the last study (Study V), the 
synbiotic combinations of a probiotic (B. lactis Bi-07) and prebiotics (GOS and/or PDX) were also 
investigated. The probiotic B. lactis was naturally shown to increase bifidobacteria and B. lactis in 
the colon model but it also increased Clostridium histolyticum group numbers. Synbiotic PDX+B. 
lactis did not change the microbial population any differently than the probiotic B. lactis or PDX 
alone, with the exception that PDX decreased B. lactis numbers. Therefore, no additional benefits 
on the microbiota composition were achieved with this combination. In contrast, synbiotic GOS+B 
lactis increased the levels of Bifidobacterium and decreased numbers of Lactobacillus, Bacteroides-
Prevotella-Porphyromonas and Clostridium histolyticum groups in comparison to baseline 
measurements. Furthermore, the composition of the microbiota was altered significantly more with 
the synbiotic than with the constituting pre- and probiotic components, as increased levels of 
bifidobacteria and decreased levels of Bacteroides-Prevotella-Porphyromonas were measured in 
relation to B. lactis and GOS fermentations alone, respectively. Also the combination of 
PDX+GOS+B.lactis had similar beneficial effects on the microbiota, with the exception that 
Bacteroides levels remained unchanged. Thus, the synbiotic combinations with GOS showed 
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significant bifidogenic effects on the microbial populations as other microbial groups were 
depressed. 
 
The metabolism of the microbiota in the colon model was significantly altered by the fermentation 
of all tested compounds. Most of the investigated prebiotics, in particular the short-chained 
oligosaccharides XOS, GOS, FOS and panose, significantly increased the levels of both acetate and 
butyrate during the simulated fermentation; propionate production was increased by 
polysaccharides, PDX and xylan. Increased butyrate concentration has often been hypothesized to 
be the mediator of beneficial effects associated with prebiotics and fiber (Hamer et al., 2008, 2009), 
and epidemiological studies show an inverse correlation between dietary fiber intake and the 
incidence of colorectal cancer (Bingham et al., 2003). Nevertheless, although several animal studies 
support the beneficial effects of butyrate on e.g. colon cancer, the evidence on humans is still 
inconsistent and inconclusive. Increased acetate and propionate production may also benefit the 
host, as these substrates are absorbed and utilised systemically in liver and muscle cells. There is 
some evidence indicating that increased dietary fiber and non-digestible carbohydrates are 
associated with increased levels of serum acetate, which could affect blood total and HDL 
cholesterol concentrations (Wolever et al., 2002). In previous in vitro studies the increased 
production of acetate and butyrate by FOS has also been demonstrated (Gibson and Wang, 1994b; 
Rycroft et al., 2001a). In this study high levels of butyrate were measured after XOS, FOS, GOS 
and panose fermentations, but bifidobacteria, the numbers of which were mainly increased by these 
substrates, does not produce this fatty acid (Salminen et al., 1998). Therefore, other microbial 
groups such as Clostridial clusters IV and XIV, containing butyrate-producers, which were not 
measured in this work, might have been affected by the fermentation of the prebiotics resulting in 
increased levels of butyrate. Alternatively, cross-feeding between different microbial groups could 
also have contributed to increased levels of butyrate as lactate utilizing microbes have been shown 
to produce butyrate (Belenguer et al., 2006; Duncan et al., 2004) and lactate levels in the colon 
simulator were very low or non-existent. The correlations that were found between bifidobacterial 
numbers and butyrate concentrations further indicate that increased levels of bifidobacteria were 
accompanied with increases in the activity of butyrate-producing microbes, either through enhanced 
cross-feeding or the increased numbers of these microbes. 
 
The concentrations of all three BCFAs (isovaleric, 2-methylbutyric and isobutyric acid) were 
significantly decreased in the whole colon model by most of the prebiotics investigated; only xylan 
did not have an effect on the BCFA levels and xylitol decreased two of them. BCFAs originate 
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exclusively from the breakdown of proteins and thus, represent a good marker for protein 
fermentation in the colon. BCFAs represent some 5 to 10% of the total SCFA produced, and may 
serve as a substituting energy for the colonocytes if butyrate availability is decreased but they do 
not, however, seem to have the same effect on the proliferation and differentiation of colonocytes as 
butyrate (Blachier et al., 2007). BCFAs themselves are not toxic substrates but are still indicators of 
proteolytic fermentation, which can result in the production of potentially toxic metabolites (indolic 
and phenolic compounds) that have been linked with adverse affects in the colon (Hughes et al., 
2000). The production of BCFA in vitro in the colon simulator reflected well the in vivo situation in 
the human gut, as increased levels of these metabolites were measured in distal parts of the colon 
model (Macfarlane et al., 1998). However, biogenic amines, those other markers of proteolytic 
fermentation, behaved differently. The highest concentrations were measured in the first vessels of 
all simulations and those concentrations decreased towards the distal vessels even though less 
carbohydrate was present in the simulator medium. This may reflect the decrease also in protein 
source originating from the inoculum and simulator medium. In the absence of a significant 
endogenous protein source, many of the tested substrates had only minor effects on biogenic amine 
production in the whole length of the colon model. GOS was the only substrate that was able to 
strongly shift the fermentation to the saccharolytic type and almost completely suppress the 
production of total biogenic amines. Biogenic amines are commonly present in living cells and in 
the colon. They are either of dietary origin, secreted from gastrointestinal cells or produced by the 
microbes; and are detoxified by monoamine and diamine oxidases in the gut mucosa and liver 
(Hughes et al., 2000). The exact function of biogenic amines in cells is still unclear, but they are 
required in large quantities in rapidly growing tissues as they are involved in DNA, RNA, protein 
and hormone synthesis (Bardócz, 1995). An increase in biogenic amines (e.g. spermine and 
spermidine) has been positively correlated with the consumption of probiotic bifidobacteria (B. 
lactis LMK512) and has been associated with reduced inflammation (Matsumoto and Benno, 2006), 
mutagenicity (Matsumoto and Benno, 2004) and improved epithelial growth in colon (Osborne and 
Seidel, 1989). However, they are also potential precursors for the formation of carcinogenic N-
nitroso compounds (Cummings and Macfarlane, 1991) and have linked to neoplastic proliferation in 
the colon (Linsalata and Russo, 2008). Some biogenic amines (histamine, tyramine) have been 
related to food spoilage and outbreaks of food poisoning (Silla Santos, 1996) and high levels have 
even been linked to migraine and hypertension (Hughes et al., 2000). Thus, low levels of these 
amines are required for normal cellular function but too high a level can exert toxic effects (Jacobs 
et al., 2009). Therefore, it is difficult to draw any definite conclusions as to whether the changes in 
biogenic amines observed with different prebiotics in these simulated colon fermentations were 
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beneficial or detrimental. As with BCFAs, decreased levels of proteolytic fermentation markers are 
preferred, especially distally in the colon, which is the predominant site of several gastrointestinal 
disorders, e.g. ulcerative colitis and colon cancer. It has been hypothesised that low concentrations 
of SCFA accompanied with increased metabolites of protein fermentation could be involved in the 
pathogenesis of these diseases (Hamer et al., 2008).  
The metabolic acitivity of the microbiota was also investigated in different parts of the colon model. 
Overall, oligosaccharides (GOS, panose, XOS, FOS) that were quickly fermented, mainly affected 
the acetate and propionate production in the whole length of the model (from vessels V1 or V2 to 
V4) and suppressed proteolytic fermentation in the proximal and middle part of the model (V1/V2 
to V3). The polyalcohol xylitol increased saccharolytic and decreased proteolytic fermentation in 
the proximal colon (V1 and V2), whereas long-chained PDX, which was still present in the distal 
part of the colon model, increased the production of all SCFAs and decreased the production of 
BCFA throughout the colon model (from vessels V1/2 to V4). The other compound with a long-
chained structure, xylan, also increased the concentrations of all three SCFAs in the whole model, 
but the levels of acetate and butyrate were significantly lower than in FOS simulations, and higher 
levels of BCFA and biogenic amines indicated a poorer fermentation of this substrate by the colonic 
microbes. GOS increased the production of acetate and propionate in all vessels and very efficiently 
suppressed the proteolytic fermentation in the proximal and middle parts of the model. The 
combination of PDX and GOS in the synbiotic product resulted in the high production of all SCFAs 
and decreased production of BCFA, also in the distal part of the model, even though the 
concentrations of both prebiotics was 50% lower than in the prebiotic fermentation simulations. The 
significant correlations between bifidobacteria and acetate and butyrate, and the inverse correlation 
with total biogenic amines and all three BCFA concentrations indicates that increased levels of 
Bifidobacterium species are specifically linked with increased saccharolytic-type fermentation. On 
the other hand, the other measured microbial groups, Lactobacillus, Cl. histolyticum and 
Bacteroides-Prevotella-Porphyromonas, have a role in the production of proteolytic metabolites, as 
significant correlations between the increased numbers of these microbes and BCFA and/or 
biogenic amines were demonstrated. The production of biogenic amines by a few Lactobacillus 
strains has been demonstrated previously (Bover-Sid and Holzapfel, 1999). 
   
The purity and good quality of samples used in in vitro tests is essential to obtain reliable results. As 
seen with some of the samples tested, other saccharides and impurities (mono-and oligosaccharides 
in GOS Bi
2
muno and unknown compounds in the HT XOS compound) may have affected the 
outcome of the study in such a manner that the results are not describing the fermentation of the 
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prebiotic candidate itself, but are instead due to impurities. In addition, the chemical properties of 
the product can make the testing of the sample impossible in vitro; for instance, the high viscosity 
of guar gum samples made reliable testing of these products impossible in vitro. It has to be noted 
as well that the commercial XOS Longlive also contained some monosaccharides (13.5% of it 
consisted of glucose, arabinose and galactose) which were difficult to separate from the product. 
Rarely are the commercial oligosaccharides pure (Rycroft et al., 2001a) and thus the commercial 
FOS also included 5% of other oligosaccharides. In human consumption, these monosaccharides are 
absorbed in the upper gastrointestinal tract and do not reach the colon. In vitro, however, these 
monosaccharides are present in the growth broth and are available as substrates for the tested 
microbes (Crittenden et al., 2002). It is therefore possible that part of the growth observed with 
Longlive XOS and FOS was due to the microbial utilization of the contaminating monosaccharides 
and not due to consumption of oligosaccharides.  
 
According to the modified definition of prebiotics (Roberfroid, 2007), a health effect must be 
demonstrated in conjunction with the prebiotic consumption. Due to the incomplete understanding 
of the “normal” microbiota composition and activity on a population basis, it is difficult to deduce 
concrete preventive or curative effects from changes in bacterial cell counts or activities only, even 
if those (such as bifidogenicity or SCFA production) are considered beneficial. Therefore, 
conclusive proof of the health effects and improvements in clinical endpoints mediated by prebiotic 
consumption should be demonstrated in controlled human intervention studies. In the future, the 
potential prebiotics and synbiotic combinations that were identified in this thesis work will be 
assessed in more detail in humans. A few of the products, namely XOS (Longlive) and B. lactis (Bi-
07); GOS and B. lactis (Bi-07); and PDX, have already entered the human intervention phase to 
investigate their prebiotic and synbiotic properties in feeding trials. It would also be interesting to 
study the novel prebiotic candidate, panose, in the human intervention phase to further assess the 
potential prebiotic properties seen in vitro. However, first the indigestibility or low digestibility of 
pure panose in the upper gastrointestinal tract should be confirmed, since only data on IMO 
mixtures exist to date. Furthermore, a novel cost-effective production method is needed for the 
production of panose as the current high price of the product will make it a commercially 
unprofitable emerging candidate.  
With regard to the Enteromix colon model, an upgrade on the current microbiota analysis is needed 
in the future to meet the high level of microbiological research today. Accumulating evidence on 
the newly identified bacterial groups and dominant species in the gut highlights the need to expand 
the analysis of the microbiota to also include other microbial groups in addition to the traditional 
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bifidobacteria, lactobacillus, Bacteroides and clostridia. For instance, numbers of butyrate-
producing genera, such as Eubacterium, Roseburia and Faecalibacterium and also other major 
components (e.g. dominating clostridial clusters) of the microbiota should be investigated in order 
to be able to draw conclusions on the selective nature of prebiotic fermentation. Furthermore, 
validation of the Enteromix colon simulator against in vivo human results is needed and can be 





The first goal of this thesis work was to screen a large group of potential and interesting prebiotic 
product candidates for their fermentation properties by colonic microbes. This was done with a 
simple in vitro screening tool which enabled the identification of several interesting candidates, 
such as xylo-oligosaccharides, lactitol and panose. 
The second goal of the study was to further characterize the prebiotic potential of these compounds 
in a model mimicking the human large intestine, in which fermentation of these compounds by the 
colonic microbiota was assessed. It was shown in vitro that XOS compounds with varying degree of 
polymerization were fermented particularly well by probiotic and endogenous B. lactis in the 
colonic microbiota, without affecting the other investigated microbial groups. Furthermore, a novel 
prebiotic candidate, panose, was identified. The fermentation of pure panose was characterized for 
the first time by human faecal microbiota, and it was shown to have bifidogenic properties in vitro 
and to decrease the growth of Bacteroides-Prevotella-Porphyromonas group. Similarly to XOS, 
panose also increased the endogenous B. lactis growth in the colon model. The microbiota 
functionality was also affected by both compounds and the production of fermentation metabolites 
was altered in a manner considered beneficial; saccharolytic-type fermentation increased at the 
expense of proteolytic fermentation.  
The third goal of the study was to compare the candidate compounds with established prebiotics. 
XOS and commercial FOS were analysed in the same colonic fermentation studies, and it was 
shown that these two oligosaccharides target different Bifidobacterium species; XOS was superior 
in terms of increasing the growth of B. lactis while FOS increased the levels of B. longum, which 
was unaffected by XOS. This finding differentiates these two oligosaccharides from each other and 
warrants further studies in the search of species-specific synbiotic products. Another comparison 
was made between the slowly-fermented PDX and the more rapidly metabolized GOS; the latter 
being superior in its modulatory capabilities on microbiota composition in these studies.  
The final aim of the study was to assess the properties of potential synbiotic product combinations. 
The prebiotic GOS and probiotic B. lactis were combined and they were shown to together 
significantly influence the composition of the microbiota more than the constituting components 
alone. The inclusion of PDX into this synbiotic further modified the activity of the microbial 
population by also decreasing the production of proteolytic metabolites in the distal part of the 
colon model. As the fermentation of GOS increased also the endogenous B. lactis growth, the 
synbiotic combination could prove to be very effective.  
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In vitro models are useful tools in studying the prebiotic fermentation in the colon. However, the 
final proof of the health effects and benefits mediated by prebiotic consumption should be 
demonstrated in controlled human intervention studies. A few of the products identified in these in 
vitro studies, namely XOS (Longlive) and B. lactis (Bi-07); GOS and B. lactis (Bi-07); and PDX, 
have already entered the human intervention phase to investigate their prebiotic and synbiotic 
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